CN105343625A - 一种排毒除湿利胆的蒲公英口服液及其制备方法 - Google Patents
一种排毒除湿利胆的蒲公英口服液及其制备方法 Download PDFInfo
- Publication number
- CN105343625A CN105343625A CN201510889661.9A CN201510889661A CN105343625A CN 105343625 A CN105343625 A CN 105343625A CN 201510889661 A CN201510889661 A CN 201510889661A CN 105343625 A CN105343625 A CN 105343625A
- Authority
- CN
- China
- Prior art keywords
- parts
- herba
- oral liquid
- radix
- herba taraxaci
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000007788 liquid Substances 0.000 title claims abstract description 66
- 210000000232 gallbladder Anatomy 0.000 title claims abstract description 42
- 238000002360 preparation method Methods 0.000 title claims abstract description 29
- 239000003053 toxin Substances 0.000 title claims abstract description 26
- 231100000765 toxin Toxicity 0.000 title claims abstract description 25
- 241000245665 Taraxacum Species 0.000 title abstract 6
- 239000003814 drug Substances 0.000 claims abstract description 101
- 238000000605 extraction Methods 0.000 claims abstract description 25
- 230000008901 benefit Effects 0.000 claims abstract description 21
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 claims abstract description 14
- 230000002829 reductive effect Effects 0.000 claims abstract description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 110
- 230000001737 promoting effect Effects 0.000 claims description 55
- 229940079593 drug Drugs 0.000 claims description 48
- 239000000843 powder Substances 0.000 claims description 30
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 25
- 238000010438 heat treatment Methods 0.000 claims description 24
- 239000000706 filtrate Substances 0.000 claims description 20
- 238000004659 sterilization and disinfection Methods 0.000 claims description 17
- 230000001603 reducing effect Effects 0.000 claims description 15
- 239000008517 radix Trichosanthis Substances 0.000 claims description 14
- 230000001954 sterilising effect Effects 0.000 claims description 14
- 230000000844 anti-bacterial effect Effects 0.000 claims description 13
- 239000010231 banlangen Substances 0.000 claims description 12
- 238000000108 ultra-filtration Methods 0.000 claims description 12
- 238000001914 filtration Methods 0.000 claims description 11
- 239000006228 supernatant Substances 0.000 claims description 11
- 229910000831 Steel Inorganic materials 0.000 claims description 8
- 238000011068 loading method Methods 0.000 claims description 8
- 238000005325 percolation Methods 0.000 claims description 8
- 239000010959 steel Substances 0.000 claims description 8
- 239000011347 resin Substances 0.000 claims description 7
- 229920005989 resin Polymers 0.000 claims description 7
- 239000004375 Dextrin Substances 0.000 claims description 6
- 229920001353 Dextrin Polymers 0.000 claims description 6
- 235000019425 dextrin Nutrition 0.000 claims description 6
- 238000004064 recycling Methods 0.000 claims description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 5
- 230000006837 decompression Effects 0.000 claims description 5
- 239000002674 ointment Substances 0.000 claims description 5
- 238000004321 preservation Methods 0.000 claims description 5
- 239000002994 raw material Substances 0.000 claims description 5
- 235000008331 Pinus X rigitaeda Nutrition 0.000 claims description 4
- 235000011613 Pinus brutia Nutrition 0.000 claims description 4
- 241000018646 Pinus brutia Species 0.000 claims description 4
- 238000010521 absorption reaction Methods 0.000 claims description 4
- 238000007598 dipping method Methods 0.000 claims description 4
- 238000010828 elution Methods 0.000 claims description 4
- 239000012567 medical material Substances 0.000 claims description 4
- 238000010992 reflux Methods 0.000 claims description 4
- 229910001220 stainless steel Inorganic materials 0.000 claims description 4
- 239000010935 stainless steel Substances 0.000 claims description 4
- 238000003756 stirring Methods 0.000 claims description 4
- 229910052799 carbon Inorganic materials 0.000 claims description 3
- 239000000284 extract Substances 0.000 claims description 3
- 239000002904 solvent Substances 0.000 claims description 3
- 230000000274 adsorptive effect Effects 0.000 claims description 2
- 239000008367 deionised water Substances 0.000 claims description 2
- 229910021641 deionized water Inorganic materials 0.000 claims description 2
- 239000012153 distilled water Substances 0.000 claims description 2
- 231100000331 toxic Toxicity 0.000 abstract description 9
- 230000002588 toxic effect Effects 0.000 abstract description 9
- 241000037831 Polygonatum sibiricum Species 0.000 abstract description 4
- 235000013399 edible fruits Nutrition 0.000 abstract description 4
- 235000008216 herbs Nutrition 0.000 abstract description 3
- 241001110058 Euphrasia pectinata Species 0.000 abstract description 2
- 241001533433 Isodon serra Species 0.000 abstract description 2
- 241001571764 Lysimachia christinae Species 0.000 abstract description 2
- 244000025254 Cannabis sativa Species 0.000 abstract 1
- 244000111489 Gardenia augusta Species 0.000 abstract 1
- 235000018958 Gardenia augusta Nutrition 0.000 abstract 1
- 241001598107 Imperata Species 0.000 abstract 1
- 241000207925 Leonurus Species 0.000 abstract 1
- 244000234609 Portulaca oleracea Species 0.000 abstract 1
- 235000001855 Portulaca oleracea Nutrition 0.000 abstract 1
- 244000179560 Prunella vulgaris Species 0.000 abstract 1
- 244000153955 Reynoutria sachalinensis Species 0.000 abstract 1
- 235000003202 Reynoutria sachalinensis Nutrition 0.000 abstract 1
- 241000915604 Scutellaria barbata Species 0.000 abstract 1
- 241000304432 Sedum sarmentosum Species 0.000 abstract 1
- 241000218989 Trichosanthes Species 0.000 abstract 1
- 240000008042 Zea mays Species 0.000 abstract 1
- 235000007244 Zea mays Nutrition 0.000 abstract 1
- 239000008186 active pharmaceutical agent Substances 0.000 abstract 1
- 229940089639 cornsilk Drugs 0.000 abstract 1
- 235000008113 selfheal Nutrition 0.000 abstract 1
- 239000001231 zea mays silk Substances 0.000 abstract 1
- 239000008280 blood Substances 0.000 description 67
- 210000004369 blood Anatomy 0.000 description 66
- 230000000694 effects Effects 0.000 description 64
- 210000004185 liver Anatomy 0.000 description 58
- 206010023126 Jaundice Diseases 0.000 description 43
- 238000011282 treatment Methods 0.000 description 39
- 208000004880 Polyuria Diseases 0.000 description 31
- 230000035619 diuresis Effects 0.000 description 31
- 230000006870 function Effects 0.000 description 29
- 208000002193 Pain Diseases 0.000 description 28
- 230000036407 pain Effects 0.000 description 28
- 230000001717 pathogenic effect Effects 0.000 description 23
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 22
- 241001465754 Metazoa Species 0.000 description 21
- 230000001154 acute effect Effects 0.000 description 20
- 231100000614 poison Toxicity 0.000 description 20
- 230000008961 swelling Effects 0.000 description 20
- 206010007247 Carbuncle Diseases 0.000 description 19
- 201000010099 disease Diseases 0.000 description 19
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 19
- 210000000941 bile Anatomy 0.000 description 18
- 210000000952 spleen Anatomy 0.000 description 17
- 238000000034 method Methods 0.000 description 16
- 238000012360 testing method Methods 0.000 description 16
- 206010042674 Swelling Diseases 0.000 description 15
- 239000003440 toxic substance Substances 0.000 description 15
- 239000000047 product Substances 0.000 description 14
- 241000411851 herbal medicine Species 0.000 description 13
- 206010017553 Furuncle Diseases 0.000 description 12
- 208000014674 injury Diseases 0.000 description 12
- 239000000463 material Substances 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- 241000196324 Embryophyta Species 0.000 description 10
- 241000628997 Flos Species 0.000 description 10
- 240000001949 Taraxacum officinale Species 0.000 description 10
- 235000005187 Taraxacum officinale ssp. officinale Nutrition 0.000 description 10
- 239000006071 cream Substances 0.000 description 10
- 206010062717 Increased upper airway secretion Diseases 0.000 description 9
- 208000006454 hepatitis Diseases 0.000 description 9
- 244000052769 pathogen Species 0.000 description 9
- 208000026435 phlegm Diseases 0.000 description 9
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 8
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 8
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 8
- 206010011224 Cough Diseases 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 8
- 101710098398 Probable alanine aminotransferase, mitochondrial Proteins 0.000 description 8
- 238000010171 animal model Methods 0.000 description 8
- 230000006378 damage Effects 0.000 description 8
- 208000001848 dysentery Diseases 0.000 description 8
- 230000036541 health Effects 0.000 description 8
- 231100000283 hepatitis Toxicity 0.000 description 8
- 210000003734 kidney Anatomy 0.000 description 8
- 230000027939 micturition Effects 0.000 description 8
- 230000000144 pharmacologic effect Effects 0.000 description 8
- 210000002784 stomach Anatomy 0.000 description 8
- 208000024891 symptom Diseases 0.000 description 8
- 201000004624 Dermatitis Diseases 0.000 description 7
- 230000017531 blood circulation Effects 0.000 description 7
- 230000037396 body weight Effects 0.000 description 7
- 230000001989 choleretic effect Effects 0.000 description 7
- 235000009508 confectionery Nutrition 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 231100000753 hepatic injury Toxicity 0.000 description 7
- 208000015181 infectious disease Diseases 0.000 description 7
- 210000004072 lung Anatomy 0.000 description 7
- 210000000582 semen Anatomy 0.000 description 7
- 230000008736 traumatic injury Effects 0.000 description 7
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 6
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 6
- 206010012735 Diarrhoea Diseases 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 206010030113 Oedema Diseases 0.000 description 6
- 241001619461 Poria <basidiomycete fungus> Species 0.000 description 6
- 208000033809 Suppuration Diseases 0.000 description 6
- 208000027418 Wounds and injury Diseases 0.000 description 6
- 208000010668 atopic eczema Diseases 0.000 description 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- 239000000796 flavoring agent Substances 0.000 description 6
- 235000019634 flavors Nutrition 0.000 description 6
- 210000004209 hair Anatomy 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 238000010926 purge Methods 0.000 description 6
- 108010082126 Alanine transaminase Proteins 0.000 description 5
- 241000700199 Cavia porcellus Species 0.000 description 5
- 206010010726 Conjunctival oedema Diseases 0.000 description 5
- 208000004930 Fatty Liver Diseases 0.000 description 5
- 206010019708 Hepatic steatosis Diseases 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 5
- 206010037660 Pyrexia Diseases 0.000 description 5
- 206010040943 Skin Ulcer Diseases 0.000 description 5
- 206010047700 Vomiting Diseases 0.000 description 5
- 210000001015 abdomen Anatomy 0.000 description 5
- 238000009825 accumulation Methods 0.000 description 5
- 230000003110 anti-inflammatory effect Effects 0.000 description 5
- 210000000988 bone and bone Anatomy 0.000 description 5
- 201000001352 cholecystitis Diseases 0.000 description 5
- 206010061428 decreased appetite Diseases 0.000 description 5
- 230000004064 dysfunction Effects 0.000 description 5
- 208000010706 fatty liver disease Diseases 0.000 description 5
- 210000002216 heart Anatomy 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 239000002398 materia medica Substances 0.000 description 5
- 239000002574 poison Substances 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 206010040872 skin infection Diseases 0.000 description 5
- 231100000019 skin ulcer Toxicity 0.000 description 5
- 235000014347 soups Nutrition 0.000 description 5
- 231100000240 steatosis hepatitis Toxicity 0.000 description 5
- 238000005728 strengthening Methods 0.000 description 5
- 235000019640 taste Nutrition 0.000 description 5
- 210000003932 urinary bladder Anatomy 0.000 description 5
- 208000004998 Abdominal Pain Diseases 0.000 description 4
- 206010000077 Abdominal mass Diseases 0.000 description 4
- 206010007882 Cellulitis Diseases 0.000 description 4
- 206010019233 Headaches Diseases 0.000 description 4
- 206010062767 Hypophysitis Diseases 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 201000007100 Pharyngitis Diseases 0.000 description 4
- 210000004100 adrenal gland Anatomy 0.000 description 4
- 235000019658 bitter taste Nutrition 0.000 description 4
- 230000036772 blood pressure Effects 0.000 description 4
- 210000001124 body fluid Anatomy 0.000 description 4
- 239000010839 body fluid Substances 0.000 description 4
- 206010006451 bronchitis Diseases 0.000 description 4
- 230000000994 depressogenic effect Effects 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 208000001780 epistaxis Diseases 0.000 description 4
- 230000003203 everyday effect Effects 0.000 description 4
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 4
- 231100000869 headache Toxicity 0.000 description 4
- 230000000968 intestinal effect Effects 0.000 description 4
- 201000007227 lymph node tuberculosis Diseases 0.000 description 4
- 230000014759 maintenance of location Effects 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 208000004396 mastitis Diseases 0.000 description 4
- 230000001681 protective effect Effects 0.000 description 4
- 230000001047 pyretic effect Effects 0.000 description 4
- 210000003786 sclera Anatomy 0.000 description 4
- RUDATBOHQWOJDD-UZVSRGJWSA-N ursodeoxycholic acid Chemical compound C([C@H]1C[C@@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-UZVSRGJWSA-N 0.000 description 4
- 229960001661 ursodiol Drugs 0.000 description 4
- 210000001835 viscera Anatomy 0.000 description 4
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 3
- 201000000736 Amenorrhea Diseases 0.000 description 3
- 206010001928 Amenorrhoea Diseases 0.000 description 3
- 241000746375 Andrographis Species 0.000 description 3
- 208000006820 Arthralgia Diseases 0.000 description 3
- 206010010741 Conjunctivitis Diseases 0.000 description 3
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 3
- 208000034507 Haematemesis Diseases 0.000 description 3
- 206010019799 Hepatitis viral Diseases 0.000 description 3
- 206010067125 Liver injury Diseases 0.000 description 3
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 3
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 3
- 229930003268 Vitamin C Natural products 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 206010001093 acute tonsillitis Diseases 0.000 description 3
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 3
- 231100000540 amenorrhea Toxicity 0.000 description 3
- 230000001754 anti-pyretic effect Effects 0.000 description 3
- -1 antiinflammatory Substances 0.000 description 3
- 239000002221 antipyretic Substances 0.000 description 3
- 208000002399 aphthous stomatitis Diseases 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 235000012000 cholesterol Nutrition 0.000 description 3
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 3
- 229960001231 choline Drugs 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 239000002934 diuretic Substances 0.000 description 3
- 230000001882 diuretic effect Effects 0.000 description 3
- 230000035622 drinking Effects 0.000 description 3
- 206010013990 dysuria Diseases 0.000 description 3
- 230000007937 eating Effects 0.000 description 3
- 239000003172 expectorant agent Substances 0.000 description 3
- 230000003419 expectorant effect Effects 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 3
- 229930182470 glycoside Natural products 0.000 description 3
- 208000006750 hematuria Diseases 0.000 description 3
- 208000002672 hepatitis B Diseases 0.000 description 3
- 230000002443 hepatoprotective effect Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 238000007689 inspection Methods 0.000 description 3
- 230000003908 liver function Effects 0.000 description 3
- 201000004792 malaria Diseases 0.000 description 3
- 231100000682 maximum tolerated dose Toxicity 0.000 description 3
- 235000013372 meat Nutrition 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 210000004706 scrotum Anatomy 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 230000035922 thirst Effects 0.000 description 3
- 208000004371 toothache Diseases 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 208000019206 urinary tract infection Diseases 0.000 description 3
- 210000002700 urine Anatomy 0.000 description 3
- 210000004291 uterus Anatomy 0.000 description 3
- 201000001862 viral hepatitis Diseases 0.000 description 3
- 235000019155 vitamin A Nutrition 0.000 description 3
- 239000011719 vitamin A Substances 0.000 description 3
- 235000019154 vitamin C Nutrition 0.000 description 3
- 239000011718 vitamin C Substances 0.000 description 3
- 229940045997 vitamin a Drugs 0.000 description 3
- 239000008812 xiaoyanlidan Substances 0.000 description 3
- XWMMEBCFHUKHEX-MRTCRTFGSA-N (+)-Taraxasterol Chemical compound C([C@@]12C)C[C@H](O)C(C)(C)[C@@H]1CC[C@]1(C)[C@@H]2CC[C@H]2[C@@H]3[C@H](C)C(=C)CC[C@]3(C)CC[C@]21C XWMMEBCFHUKHEX-MRTCRTFGSA-N 0.000 description 2
- QMKPCZNFLUQTJZ-UHFFFAOYSA-N (4aR)-10c-Hydroxy-1t.2c.4ar.6at.6bc.9.9.12ac-octamethyl-(8atH.12btH.14acH.14btH)-docosahydro-picen Natural products CC1CCC2(C)CCC3(C)C(CCC4C5(C)CCC(O)C(C)(C)C5CCC34C)C2C1C QMKPCZNFLUQTJZ-UHFFFAOYSA-N 0.000 description 2
- BAHMQESJBKGPTE-UHFFFAOYSA-N 1,5,8-trimethyl-3a,4-dihydroazuleno[6,5-b]furan-2,6-dione Chemical compound C1C2OC(=O)C(C)=C2C=C2C(C)=CC(=O)C2=C1C BAHMQESJBKGPTE-UHFFFAOYSA-N 0.000 description 2
- 208000002874 Acne Vulgaris Diseases 0.000 description 2
- 208000000197 Acute Cholecystitis Diseases 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 206010008614 Cholecystitis acute Diseases 0.000 description 2
- 206010010774 Constipation Diseases 0.000 description 2
- 208000034656 Contusions Diseases 0.000 description 2
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 2
- 208000005171 Dysmenorrhea Diseases 0.000 description 2
- 206010013935 Dysmenorrhoea Diseases 0.000 description 2
- 208000004232 Enteritis Diseases 0.000 description 2
- 206010015150 Erythema Diseases 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 206010060710 Galactostasis Diseases 0.000 description 2
- 208000007882 Gastritis Diseases 0.000 description 2
- 208000037319 Hepatitis infectious Diseases 0.000 description 2
- 206010019909 Hernia Diseases 0.000 description 2
- COHYTHOBJLSHDF-UHFFFAOYSA-N Indigo Chemical compound N1C2=CC=CC=C2C(=O)C1=C1C(=O)C2=CC=CC=C2N1 COHYTHOBJLSHDF-UHFFFAOYSA-N 0.000 description 2
- 229920001202 Inulin Polymers 0.000 description 2
- WNGSUWLDMZFYNZ-UHFFFAOYSA-N Leonurine Chemical compound COC1=CC(C(=O)OCCCCN=C(N)N)=CC(OC)=C1O WNGSUWLDMZFYNZ-UHFFFAOYSA-N 0.000 description 2
- ABSPRNADVQNDOU-UHFFFAOYSA-N Menaquinone 1 Natural products C1=CC=C2C(=O)C(CC=C(C)C)=C(C)C(=O)C2=C1 ABSPRNADVQNDOU-UHFFFAOYSA-N 0.000 description 2
- 208000019255 Menstrual disease Diseases 0.000 description 2
- 206010027514 Metrorrhagia Diseases 0.000 description 2
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 2
- 206010068319 Oropharyngeal pain Diseases 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 241000241413 Propolis Species 0.000 description 2
- 241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- 244000269722 Thea sinensis Species 0.000 description 2
- 108090000340 Transaminases Proteins 0.000 description 2
- 102000003929 Transaminases Human genes 0.000 description 2
- 206010053476 Traumatic haemorrhage Diseases 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 206010052428 Wound Diseases 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 206010000496 acne Diseases 0.000 description 2
- 201000004484 acute conjunctivitis Diseases 0.000 description 2
- FSLPMRQHCOLESF-UHFFFAOYSA-N alpha-amyrenol Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C)C(C)C5C4=CCC3C21C FSLPMRQHCOLESF-UHFFFAOYSA-N 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 230000036528 appetite Effects 0.000 description 2
- 235000019789 appetite Nutrition 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- QUKGYYKBILRGFE-UHFFFAOYSA-N benzyl acetate Chemical compound CC(=O)OCC1=CC=CC=C1 QUKGYYKBILRGFE-UHFFFAOYSA-N 0.000 description 2
- JFSHUTJDVKUMTJ-QHPUVITPSA-N beta-amyrin Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C JFSHUTJDVKUMTJ-QHPUVITPSA-N 0.000 description 2
- QQFMRPIKDLHLKB-UHFFFAOYSA-N beta-amyrin Natural products CC1C2C3=CCC4C5(C)CCC(O)C(C)(C)C5CCC4(C)C3(C)CCC2(C)CCC1(C)C QQFMRPIKDLHLKB-UHFFFAOYSA-N 0.000 description 2
- PDNLMONKODEGSE-UHFFFAOYSA-N beta-amyrin acetate Natural products CC(=O)OC1CCC2(C)C(CCC3(C)C4(C)CCC5(C)CCC(C)(C)CC5C4=CCC23C)C1(C)C PDNLMONKODEGSE-UHFFFAOYSA-N 0.000 description 2
- 208000002352 blister Diseases 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 208000034526 bruise Diseases 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 230000001914 calming effect Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- ZZIALNLLNHEQPJ-UHFFFAOYSA-N coumestrol Chemical compound C1=C(O)C=CC2=C1OC(=O)C1=C2OC2=CC(O)=CC=C12 ZZIALNLLNHEQPJ-UHFFFAOYSA-N 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 230000002951 depilatory effect Effects 0.000 description 2
- 210000001198 duodenum Anatomy 0.000 description 2
- 231100000321 erythema Toxicity 0.000 description 2
- 210000001508 eye Anatomy 0.000 description 2
- 230000004438 eyesight Effects 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 229960000304 folic acid Drugs 0.000 description 2
- 235000019152 folic acid Nutrition 0.000 description 2
- 239000011724 folic acid Substances 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 150000002338 glycosides Chemical class 0.000 description 2
- 230000037308 hair color Effects 0.000 description 2
- 208000035861 hematochezia Diseases 0.000 description 2
- 208000014617 hemorrhoid Diseases 0.000 description 2
- 230000023597 hemostasis Effects 0.000 description 2
- 206010019692 hepatic necrosis Diseases 0.000 description 2
- 230000007866 hepatic necrosis Effects 0.000 description 2
- 208000005252 hepatitis A Diseases 0.000 description 2
- 210000003494 hepatocyte Anatomy 0.000 description 2
- 235000020256 human milk Nutrition 0.000 description 2
- 210000004251 human milk Anatomy 0.000 description 2
- 210000003026 hypopharynx Anatomy 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 2
- 229940029339 inulin Drugs 0.000 description 2
- 230000009545 invasion Effects 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 238000002386 leaching Methods 0.000 description 2
- UWKAYLJWKGQEPM-LBPRGKRZSA-N linalyl acetate Chemical compound CC(C)=CCC[C@](C)(C=C)OC(C)=O UWKAYLJWKGQEPM-LBPRGKRZSA-N 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 210000005229 liver cell Anatomy 0.000 description 2
- 201000003453 lung abscess Diseases 0.000 description 2
- 201000003265 lymphadenitis Diseases 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000004089 microcirculation Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 231100000915 pathological change Toxicity 0.000 description 2
- 230000036285 pathological change Effects 0.000 description 2
- 235000019175 phylloquinone Nutrition 0.000 description 2
- 239000011772 phylloquinone Substances 0.000 description 2
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 2
- MBWXNTAXLNYFJB-NKFFZRIASA-N phylloquinone Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CCC[C@H](C)CCC[C@H](C)CCCC(C)C)=C(C)C(=O)C2=C1 MBWXNTAXLNYFJB-NKFFZRIASA-N 0.000 description 2
- 229960001898 phytomenadione Drugs 0.000 description 2
- 208000037920 primary disease Diseases 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 229940069949 propolis Drugs 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- NGFFRJBGMSPDMS-UHFFFAOYSA-N psi-Taraxasterol Natural products CC12CCC(O)C(C)(C)C1CCC1(C)C2CCC2C3C(C)C(C)=CCC3(C)CCC21C NGFFRJBGMSPDMS-UHFFFAOYSA-N 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- 238000010791 quenching Methods 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 229960002477 riboflavin Drugs 0.000 description 2
- 230000000630 rising effect Effects 0.000 description 2
- 239000002689 soil Substances 0.000 description 2
- 230000004206 stomach function Effects 0.000 description 2
- 239000004575 stone Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 235000021147 sweet food Nutrition 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- HUTYZQWCTWWXND-NCTFTGAASA-N taraxasterol Natural products C[C@H]1[C@H]2C3=CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]4(C)[C@]3(C)C[C@H](O)[C@@]2(C)CCC1=C HUTYZQWCTWWXND-NCTFTGAASA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 229940126680 traditional chinese medicines Drugs 0.000 description 2
- 230000002936 tranquilizing effect Effects 0.000 description 2
- 201000008827 tuberculosis Diseases 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- 239000002435 venom Substances 0.000 description 2
- 210000001048 venom Anatomy 0.000 description 2
- 231100000611 venom Toxicity 0.000 description 2
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 description 1
- JLTCWSBVQSZVLT-CDIPANDDSA-N (2s)-n-[(2s)-6-amino-1-[(2-amino-2-oxoethyl)amino]-1-oxohexan-2-yl]-1-[(4r,7s,10s,13s,16s,19r)-19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-benzyl-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosan Chemical compound NCCCC[C@@H](C(=O)NCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](N)CSSC1.C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 JLTCWSBVQSZVLT-CDIPANDDSA-N 0.000 description 1
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 1
- UUTKICFRNVKFRG-WDSKDSINSA-N (4R)-3-[oxo-[(2S)-5-oxo-2-pyrrolidinyl]methyl]-4-thiazolidinecarboxylic acid Chemical compound OC(=O)[C@@H]1CSCN1C(=O)[C@H]1NC(=O)CC1 UUTKICFRNVKFRG-WDSKDSINSA-N 0.000 description 1
- XBZYWSMVVKYHQN-MYPRUECHSA-N (4as,6as,6br,8ar,9r,10s,12ar,12br,14bs)-10-hydroxy-2,2,6a,6b,9,12a-hexamethyl-9-[(sulfooxy)methyl]-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12,12a,12b,13,14b-icosahydropicene-4a-carboxylic acid Chemical compound C1C[C@H](O)[C@@](C)(COS(O)(=O)=O)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C XBZYWSMVVKYHQN-MYPRUECHSA-N 0.000 description 1
- NCYCYZXNIZJOKI-IOUUIBBYSA-N 11-cis-retinal Chemical compound O=C/C=C(\C)/C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-IOUUIBBYSA-N 0.000 description 1
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 244000296912 Ageratum conyzoides Species 0.000 description 1
- 235000004405 Ageratum conyzoides Nutrition 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 206010002368 Anger Diseases 0.000 description 1
- 206010003011 Appendicitis Diseases 0.000 description 1
- 241000086254 Arnica montana Species 0.000 description 1
- 244000252230 Artemisia stelleriana Species 0.000 description 1
- 241001480043 Arthrodermataceae Species 0.000 description 1
- 241000208838 Asteraceae Species 0.000 description 1
- 208000004429 Bacillary Dysentery Diseases 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 241000255789 Bombyx mori Species 0.000 description 1
- 206010006326 Breath odour Diseases 0.000 description 1
- 206010006458 Bronchitis chronic Diseases 0.000 description 1
- 206010006784 Burning sensation Diseases 0.000 description 1
- 238000011735 C3H mouse Methods 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241001164374 Calyx Species 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 235000016535 Capraria biflora Nutrition 0.000 description 1
- 208000001378 Carbon Tetrachloride Poisoning Diseases 0.000 description 1
- 208000013017 Child Nutrition disease Diseases 0.000 description 1
- 206010008531 Chills Diseases 0.000 description 1
- 239000004380 Cholic acid Substances 0.000 description 1
- 206010008796 Chromaturia Diseases 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 206010009152 Chronic tonsillitis Diseases 0.000 description 1
- IFYMEZNJCAQUME-APKWKYNESA-N Chrysanthemaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C1OC2(C)CC(O)CC(C)(C)C2=C1)C=CC=C(/C)C=CC3=C(C)CC(O)CC3(C)C IFYMEZNJCAQUME-APKWKYNESA-N 0.000 description 1
- 235000000604 Chrysanthemum parthenium Nutrition 0.000 description 1
- 241000756943 Codonopsis Species 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 241000186216 Corynebacterium Species 0.000 description 1
- 206010012442 Dermatitis contact Diseases 0.000 description 1
- 206010048768 Dermatosis Diseases 0.000 description 1
- 208000005373 Dyshidrotic Eczema Diseases 0.000 description 1
- 206010013954 Dysphoria Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 208000004145 Endometritis Diseases 0.000 description 1
- 201000000297 Erysipelas Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 208000008265 Favism Diseases 0.000 description 1
- 239000004211 Flavoxanthin Substances 0.000 description 1
- JRHJXXLCNATYLS-NGZWBNMCSA-N Flavoxanthin Chemical compound C/C([C@H]1C=C2C(C)(C)C[C@H](O)C[C@@]2(C)O1)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C JRHJXXLCNATYLS-NGZWBNMCSA-N 0.000 description 1
- QHUMOJKEVAPSCY-JOJDNVQPSA-N Flavoxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C1(C)OC2(C)CC(O)CC(C)(C)C2=C1)C=CC=C(/C)C=CC3C(=CC(O)CC3(C)C)C QHUMOJKEVAPSCY-JOJDNVQPSA-N 0.000 description 1
- 206010016952 Food poisoning Diseases 0.000 description 1
- 208000019331 Foodborne disease Diseases 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 102100035695 Gamma-aminobutyric acid receptor-associated protein Human genes 0.000 description 1
- XJMPAUZQVRGFRE-SCHFUKFYSA-N Gardenoside Natural products O=C(OC)C=1[C@H]2[C@H]([C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)OC=1)[C@@](O)(CO)C=C2 XJMPAUZQVRGFRE-SCHFUKFYSA-N 0.000 description 1
- 208000005577 Gastroenteritis Diseases 0.000 description 1
- 206010017915 Gastroenteritis shigella Diseases 0.000 description 1
- IBFYXTRXDNAPMM-BVTMAQQCSA-N Geniposide Chemical compound O([C@@H]1OC=C([C@@H]2[C@H]1C(=CC2)CO)C(=O)OC)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O IBFYXTRXDNAPMM-BVTMAQQCSA-N 0.000 description 1
- IBFYXTRXDNAPMM-FZEIBHLUSA-N Geniposide Natural products COC(=O)C1=CO[C@@H](O[C@H]2O[C@@H](CO)[C@H](O)[C@@H](O)[C@@H]2O)[C@H]2[C@@H]1CC=C2CO IBFYXTRXDNAPMM-FZEIBHLUSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010018444 Glucose-6-phosphate dehydrogenase deficiency Diseases 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 206010018612 Gonorrhoea Diseases 0.000 description 1
- 208000032139 Halitosis Diseases 0.000 description 1
- 241000590002 Helicobacter pylori Species 0.000 description 1
- 208000000616 Hemoptysis Diseases 0.000 description 1
- 206010019705 Hepatic pain Diseases 0.000 description 1
- 208000007514 Herpes zoster Diseases 0.000 description 1
- 101001001372 Homo sapiens Gamma-aminobutyric acid receptor-associated protein Proteins 0.000 description 1
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 1
- 206010020565 Hyperaemia Diseases 0.000 description 1
- 208000008454 Hyperhidrosis Diseases 0.000 description 1
- 235000017309 Hypericum perforatum Nutrition 0.000 description 1
- 206010020710 Hyperphagia Diseases 0.000 description 1
- 206010020741 Hyperpyrexia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010021118 Hypotonia Diseases 0.000 description 1
- 241001662043 Icterus Species 0.000 description 1
- 244000283207 Indigofera tinctoria Species 0.000 description 1
- 235000000177 Indigofera tinctoria Nutrition 0.000 description 1
- 208000006877 Insect Bites and Stings Diseases 0.000 description 1
- 206010061245 Internal injury Diseases 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- 241000334160 Isatis Species 0.000 description 1
- 241000334154 Isatis tinctoria Species 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- 241001183964 Isodon lophanthoides Species 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- CMUNUTVVOOHQPW-LURJTMIESA-N L-proline betaine Chemical compound C[N+]1(C)CCC[C@H]1C([O-])=O CMUNUTVVOOHQPW-LURJTMIESA-N 0.000 description 1
- 241000207923 Lamiaceae Species 0.000 description 1
- VELYAQRXBJLJAK-MJSCJBMMSA-N Leonuridine Chemical compound C12C(C)(O)CC(O)C2C=COC1O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VELYAQRXBJLJAK-MJSCJBMMSA-N 0.000 description 1
- 240000007890 Leonurus cardiaca Species 0.000 description 1
- 235000000802 Leonurus cardiaca ssp. villosus Nutrition 0.000 description 1
- 241000801118 Lepidium Species 0.000 description 1
- 241000589902 Leptospira Species 0.000 description 1
- 208000015924 Lithiasis Diseases 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- 244000241838 Lycium barbarum Species 0.000 description 1
- 235000015459 Lycium barbarum Nutrition 0.000 description 1
- 235000015463 Lycium carolinianum Nutrition 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000192041 Micrococcus Species 0.000 description 1
- 206010050819 Musculoskeletal chest pain Diseases 0.000 description 1
- VLCHQFXSBHIBRV-KNNWKXJLSA-N Mussaenosidic acid Natural products O=C(O)C=1[C@@H]2[C@H]([C@H](O[C@@H]3[C@@H](O)[C@H](O)[C@H](O)[C@@H](CO)O3)OC=1)[C@](O)(C)CC2 VLCHQFXSBHIBRV-KNNWKXJLSA-N 0.000 description 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 1
- 241000588653 Neisseria Species 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 208000007117 Oral Ulcer Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 206010033078 Otitis media Diseases 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 244000131316 Panax pseudoginseng Species 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 240000004928 Paspalum scrobiculatum Species 0.000 description 1
- 235000003675 Paspalum scrobiculatum Nutrition 0.000 description 1
- 206010034133 Pathogen resistance Diseases 0.000 description 1
- 208000029082 Pelvic Inflammatory Disease Diseases 0.000 description 1
- 241000382362 Persicaria tinctoria Species 0.000 description 1
- 208000005374 Poisoning Diseases 0.000 description 1
- 241000219304 Portulacaceae Species 0.000 description 1
- 102000005320 Posterior Pituitary Hormones Human genes 0.000 description 1
- 108010070873 Posterior Pituitary Hormones Proteins 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000208476 Primulaceae Species 0.000 description 1
- 241000588769 Proteus <enterobacteria> Species 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 208000004680 Rectal Fistula Diseases 0.000 description 1
- 206010057071 Rectal tenesmus Diseases 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 240000001341 Reynoutria japonica Species 0.000 description 1
- 102000004330 Rhodopsin Human genes 0.000 description 1
- 108090000820 Rhodopsin Proteins 0.000 description 1
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
- 206010039587 Scarlet Fever Diseases 0.000 description 1
- 241001529553 Scoparia <angiosperm> Species 0.000 description 1
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 description 1
- YSIFYNVXJOGADM-KDYWOABDSA-N Shanzhiside Chemical compound O([C@H]1[C@H]2[C@@H](C(=CO1)C(O)=O)[C@H](O)C[C@@]2(O)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O YSIFYNVXJOGADM-KDYWOABDSA-N 0.000 description 1
- PVPIPGMAEAJMTH-UHFFFAOYSA-N Shanzhiside Natural products OCC1OC(OC2OC=C(C3C(O)CC(O)C23)C(=O)O)C(O)C(O)C1O PVPIPGMAEAJMTH-UHFFFAOYSA-N 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 206010072170 Skin wound Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 208000004078 Snake Bites Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 206010041956 Stasis syndrome Diseases 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- 241000193990 Streptococcus sp. 'group B' Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 201000002014 Suppurative Otitis Media Diseases 0.000 description 1
- 241000282894 Sus scrofa domesticus Species 0.000 description 1
- 235000015360 Taraxacum officinale ssp. ceratophorum Nutrition 0.000 description 1
- 241000130764 Tinea Species 0.000 description 1
- 208000002474 Tinea Diseases 0.000 description 1
- HZYXFRGVBOPPNZ-UHFFFAOYSA-N UNPD88870 Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)=CCC(CC)C(C)C)C1(C)CC2 HZYXFRGVBOPPNZ-UHFFFAOYSA-N 0.000 description 1
- 206010046274 Upper gastrointestinal haemorrhage Diseases 0.000 description 1
- 206010046306 Upper respiratory tract infection Diseases 0.000 description 1
- 206010046788 Uterine haemorrhage Diseases 0.000 description 1
- 206010046814 Uterine prolapse Diseases 0.000 description 1
- 206010046910 Vaginal haemorrhage Diseases 0.000 description 1
- 241000607626 Vibrio cholerae Species 0.000 description 1
- SZCBXWMUOPQSOX-LOFNIBRQSA-N Violaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C12OC1(C)CC(O)CC2(C)C)C=CC=C(/C)C=CC34OC3(C)CC(O)CC4(C)C SZCBXWMUOPQSOX-LOFNIBRQSA-N 0.000 description 1
- 239000004213 Violaxanthin Substances 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 206010048245 Yellow skin Diseases 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 208000019790 abdominal distention Diseases 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 238000001467 acupuncture Methods 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 208000012873 acute gastroenteritis Diseases 0.000 description 1
- 208000016150 acute pharyngitis Diseases 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 239000002390 adhesive tape Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 206010002156 anal fistula Diseases 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000001142 anti-diarrhea Effects 0.000 description 1
- 230000001166 anti-perspirative effect Effects 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 239000003213 antiperspirant Substances 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- VGLLGNISLBPZNL-RBUKDIBWSA-N arborescoside Natural products O=C(OC)C=1[C@@H]2C([C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)OC=1)=C(CO)CC2 VGLLGNISLBPZNL-RBUKDIBWSA-N 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229940007550 benzyl acetate Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 208000005634 blind loop syndrome Diseases 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229960005069 calcium Drugs 0.000 description 1
- 235000001465 calcium Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- 238000013245 carbon tetrachloride model Methods 0.000 description 1
- 150000001746 carotenes Chemical class 0.000 description 1
- 235000005473 carotenes Nutrition 0.000 description 1
- 210000003986 cell retinal photoreceptor Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000002279 cholagogic effect Effects 0.000 description 1
- 201000001883 cholelithiasis Diseases 0.000 description 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
- 235000019416 cholic acid Nutrition 0.000 description 1
- 229960002471 cholic acid Drugs 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 208000007451 chronic bronchitis Diseases 0.000 description 1
- 210000000078 claw Anatomy 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 230000001427 coherent effect Effects 0.000 description 1
- 208000027744 congestion Diseases 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 208000010247 contact dermatitis Diseases 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 229940108928 copper Drugs 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 230000000120 cytopathologic effect Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 1
- 230000037304 dermatophytes Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 206010013023 diphtheria Diseases 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 239000003221 ear drop Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000007824 enzymatic assay Methods 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 238000002481 ethanol extraction Methods 0.000 description 1
- 239000000469 ethanolic extract Substances 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 210000004709 eyebrow Anatomy 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 208000024756 faint Diseases 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 210000003746 feather Anatomy 0.000 description 1
- 239000003337 fertilizer Substances 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 208000017561 flaccidity Diseases 0.000 description 1
- 235000019243 flavoxanthin Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000008838 gegenqinlian Substances 0.000 description 1
- XTLWNMXYCHABQH-UHFFFAOYSA-N germanicol Natural products CC1(C)CCC2(C)CCC3(C)C(CCC4(C)C5(C)CCC(O)C(C)(C)C5CCC34C)C2=C1 XTLWNMXYCHABQH-UHFFFAOYSA-N 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 208000001786 gonorrhea Diseases 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 230000003779 hair growth Effects 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 208000024557 hepatobiliary disease Diseases 0.000 description 1
- 230000003118 histopathologic effect Effects 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 230000037315 hyperhidrosis Effects 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- COHYTHOBJLSHDF-BUHFOSPRSA-N indigo dye Chemical compound N\1C2=CC=CC=C2C(=O)C/1=C1/C(=O)C2=CC=CC=C2N1 COHYTHOBJLSHDF-BUHFOSPRSA-N 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 229940090044 injection Drugs 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 230000001983 lactogenic effect Effects 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- UWKAYLJWKGQEPM-UHFFFAOYSA-N linalool acetate Natural products CC(C)=CCCC(C)(C=C)OC(C)=O UWKAYLJWKGQEPM-UHFFFAOYSA-N 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 231100001252 long-term toxicity Toxicity 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 235000001055 magnesium Nutrition 0.000 description 1
- 229940091250 magnesium supplement Drugs 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 210000000713 mesentery Anatomy 0.000 description 1
- HVHKMUMXERBUAN-IFADSCNNSA-N mesobilirubin IXalpha Chemical compound N1C(=O)C(CC)=C(C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C)C(=O)N\3)CC)N2)CCC(O)=O)N1 HVHKMUMXERBUAN-IFADSCNNSA-N 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- XJMPAUZQVRGFRE-AYDWLWLASA-N methyl (1s,4as,7s,7as)-7-hydroxy-7-(hydroxymethyl)-1-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4a,7a-dihydro-1h-cyclopenta[c]pyran-4-carboxylate Chemical compound O([C@@H]1OC=C([C@@H]2[C@H]1[C@](C=C2)(O)CO)C(=O)OC)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O XJMPAUZQVRGFRE-AYDWLWLASA-N 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 201000002266 mite infestation Diseases 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 201000005111 ocular hyperemia Diseases 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 229940100691 oral capsule Drugs 0.000 description 1
- 229940096978 oral tablet Drugs 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 238000010422 painting Methods 0.000 description 1
- 235000012771 pancakes Nutrition 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000013618 particulate matter Substances 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229960000292 pectin Drugs 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 201000001245 periodontitis Diseases 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 206010034754 petechiae Diseases 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 201000011414 pompholyx Diseases 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 235000007686 potassium Nutrition 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000002633 protecting effect Effects 0.000 description 1
- 230000009325 pulmonary function Effects 0.000 description 1
- 239000009806 pulsatillae Substances 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 238000004080 punching Methods 0.000 description 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 208000020615 rectal carcinoma Diseases 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 238000000518 rheometry Methods 0.000 description 1
- 235000019192 riboflavin Nutrition 0.000 description 1
- 239000002151 riboflavin Substances 0.000 description 1
- 201000004700 rosacea Diseases 0.000 description 1
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 1
- 229960002646 scopolamine Drugs 0.000 description 1
- 208000008742 seborrheic dermatitis Diseases 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 201000005113 shigellosis Diseases 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 230000002048 spasmolytic effect Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000005982 spleen dysfunction Effects 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- CMUNUTVVOOHQPW-ZCFIWIBFSA-N stachydrine Natural products C[N+]1(C)CCC[C@@H]1C([O-])=O CMUNUTVVOOHQPW-ZCFIWIBFSA-N 0.000 description 1
- 238000012109 statistical procedure Methods 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- HCXVJBMSMIARIN-PHZDYDNGSA-N stigmasterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)/C=C/[C@@H](CC)C(C)C)[C@@]1(C)CC2 HCXVJBMSMIARIN-PHZDYDNGSA-N 0.000 description 1
- 229940032091 stigmasterol Drugs 0.000 description 1
- 235000016831 stigmasterol Nutrition 0.000 description 1
- BFDNMXAIBMJLBB-UHFFFAOYSA-N stigmasterol Natural products CCC(C=CC(C)C1CCCC2C3CC=C4CC(O)CCC4(C)C3CCC12C)C(C)C BFDNMXAIBMJLBB-UHFFFAOYSA-N 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 206010042772 syncope Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- GGGUGZHBAOMSFJ-GADYQYKKSA-N taraxerol Chemical compound CC([C@@H]1CC2)(C)[C@@H](O)CC[C@]1(C)[C@@H]1[C@]2(C)C2=CC[C@@]3(C)CCC(C)(C)C[C@H]3[C@]2(C)CC1 GGGUGZHBAOMSFJ-GADYQYKKSA-N 0.000 description 1
- HYTFUKZLSYXRDX-UHFFFAOYSA-N taraxerol Natural products CC1CCCC2C3(C)CCC4(C)C5CC(C)(C)CCC5(C)C=CC4(C)C3C(O)CC12C HYTFUKZLSYXRDX-UHFFFAOYSA-N 0.000 description 1
- 208000012271 tenesmus Diseases 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 206010044008 tonsillitis Diseases 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 235000019245 violaxanthin Nutrition 0.000 description 1
- SZCBXWMUOPQSOX-PSXNNQPNSA-N violaxanthin Chemical compound C(\[C@@]12[C@](O1)(C)C[C@H](O)CC2(C)C)=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(\C)/C=C/C=C(\C)/C=C/[C@]1(C(C[C@@H](O)C2)(C)C)[C@]2(C)O1 SZCBXWMUOPQSOX-PSXNNQPNSA-N 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- MECHNRXZTMCUDQ-RKHKHRCZSA-N vitamin D2 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)/C=C/[C@H](C)C(C)C)=C\C=C1\C[C@@H](O)CCC1=C MECHNRXZTMCUDQ-RKHKHRCZSA-N 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 230000037314 wound repair Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/233—Bupleurum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/288—Taraxacum (dandelion)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
- A61K36/315—Isatis, e.g. Dyer's woad
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/41—Crassulaceae (Stonecrop family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/42—Cucurbitaceae (Cucumber family)
- A61K36/428—Trichosanthes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/533—Leonurus (motherwort)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/536—Prunella or Brunella (selfheal)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/539—Scutellaria (skullcap)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/704—Polygonum, e.g. knotweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/74—Rubiaceae (Madder family)
- A61K36/744—Gardenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/80—Scrophulariaceae (Figwort family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/80—Scrophulariaceae (Figwort family)
- A61K36/804—Rehmannia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8969—Polygonatum (Solomon's seal)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/55—Liquid-liquid separation; Phase separation
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明提供一种排毒除湿利胆的蒲公英口服液,包括以下重量份数的原料药:蒲公英10~50份,茵陈10~20份,溪黄草10~20份,夏枯草10~20份,柴胡10~20份,白芍10~20份,玉米须10~20份,白茅根10~20份,虎杖10~20份,小米草10~20份,半枝莲10~20份,垂盆草10~20份,益母草10~20份,天花粉10~20份,栀子10~20份,墨旱莲10~20份,黄精10~20份,马齿苋10~20份,生地10~20份,板蓝根10~20份,金钱草10~20份。本发明大大改进中药提取技术,使得中药的有毒成分降到最低,可以使人体吸收,大大提高其利用率。
Description
技术领域
本发明涉及含有来源于植物、动物或矿物原料的医用保健品,特别涉及一种排毒除湿利胆的蒲公英口服液及其制备方法。
背景技术
看中医时,我们常会听医生说“湿热”。那么,什么是湿热,湿热有哪些表现,应注意什么问题呢?要明白湿热,先应了解什么叫湿,什么叫热。所谓湿,即通常所说的水湿,它有外湿和内湿的区分。外湿是由于气候潮湿或涉水淋雨或居室潮湿,使外来水湿入侵人体而引起;内湿是一种病理产物,常与消化功能有关。中医认为脾有“运化水湿”的功能,若体虚消化不良或暴饮暴食,吃过多油腻、甜食,则脾就不能正常运化而使“水湿内停”;且脾虚的人也易招来外湿的入侵,外湿也常因阻脾胃使湿从内生,所以两者是既独立又关联的。所谓热,则是一种热象。而湿热中的热是与湿同时存在的,或因夏秋季节天热湿重,湿与热合并入侵人体,或因湿久留不除而化热,或因“阳热体质”而使湿“从阳化热”,因此,湿与热同时存在是很常见的。湿热体质面部和鼻尖总是油光发亮,易生粉刺、疮疖,常感到口苦、口臭或嘴里有异味,经常大便粘滞不爽,小便有发热感,尿色发黄,女性常带下色黄,男性阴囊总是潮湿多汗。发病倾向:湿热体质的人易患疮疖、黄疸、火热病等征。
湿热的一般表现为:肢体沉重,发热多在午后明显,并不因出汗而减轻;舌苔黄腻,脉数。具体表现因湿热所在不同的部位而有差别:在皮肉则为湿疹或疔疱;在关节筋脉则局部肿痛。但通常所说的湿热多指湿热深入脏腑,特别是脾胃的湿热,可见脘闷腹满,恶心厌食,便溏稀,尿短赤,脉濡数;其它如肝胆湿热表现为肝区胀痛,口苦食欲差,或身目发黄,或发热怕冷交替,脉弦数;膀胱湿热见尿频、尿急,涩少而痛,色黄浊;大肠湿热见腹痛腹泻,甚至里急后重,泻下脓血便,肛门灼热、口渴。
湿热的治疗,一般要分湿重还是热重。湿重的化湿为主,可选用六一散、三仁汤、平胃散;热重以清热为主,可选用连朴饮、茵陈蒿汤、葛根芩连汤。在这一原则下,再根据某些特殊表现选择相应的药,如湿疹、疔疱,加野菊花、地丁草、苦参、白藓皮;关节肿痛加桂枝、忍冬藤、桑枝等;腹泻甚至痢疾加白头翁汤、地榆、车前子等;阴囊湿疹、睾丸胀痛、白带黄臭可加龙胆草、苦参等;血尿可加小蓟草、茅根、石苇、扁蓄等。此外,因热往往依附湿而存在,所以,应注意起居环境的改善和饮食调理,不宜暴饮暴食、酗酒,少吃甜食。中医认为肝炎多属于湿热蕴结致使胆液外泄侵及皮肤、巩膜等处而发生黄疽,因肝失疏泄,脾失健运而发生食欲不振、恶心呕吐等症状,治疗上宜采取“清热利湿、疏肝利胆”的方法。
我们经过77例急性黄疽型肝炎应用蒲公英制剂治疗的临床观察,初步可看出蒲公英对退黄、降低谷丙转氨酶有一定的作用,并在治疗30天内使89.6%的急性黄疽型肝炎患者临床治愈,在云南等地被认为是治疗病毒性肝炎较好的药物,与大青叶治疗肝胆疗效相似。
药理试验结果表明,蒲公英煎剂与注射液有降低四氯化碳引致的大白鼠谷丙转氨酶升高的作用,并能减轻其肝损害,有一定的利胆作用,这可能是蒲公英治疗急性黄疽型肝炎的药理学基础。鉴于蒲公英制剂对实验动物脑垂体,肾上腺等组织无损害作用,临床上未发现任何副作用,而且药源广泛,具有较好的杀菌、保肝、利胆等作用,值得进一步研究其有效成分,改革剂型,扩大临床应用范围。
生蒲公英富含维生素A、维生素C及钾,也含有铁、钙、维生素B2、维生素B1、镁、维生素B6、叶酸及铜。具体的元素含量主要是水分,每60克生蒲公英叶含水分86%,蛋白质1.6克,碳水化合物5.3克,热量约有108.8千焦。蒲公英植物体中含有蒲公英醇、蒲公英素、胆碱、有机酸、菊糖等多种健康营养成分。性味甘,微苦,寒。归肝、胃经。有利尿、缓泻、退黄疸、利胆等功效。治热毒、痈肿、疮疡、内痈、目赤肿痛、湿热、黄疸、小便淋沥涩痛、疔疮肿毒,乳痈,瘰疬,牙痛,目赤,咽痛,肺痈,肠痈,湿热黄疸,热淋涩痛。治急性乳腺炎,淋巴腺炎,瘰疬,疔毒疮肿,急性结膜炎,感冒发热,急性扁桃体炎,急性支气管炎,胃炎,肝炎,胆囊炎,尿路感染等。蒲公英可生吃、炒食、做汤,是药食兼用的植物。
蒲公英清热解毒,利尿散结。治急性乳腺炎,淋巴腺炎,瘰疬,疔毒疮肿,急性结膜炎,感冒发热,急性扁桃体炎,急性支气管炎,胃炎,肝炎,胆囊炎,尿路感染。《唐本草》:主妇人乳痈肿。《本草图经》:敷疮,又治恶刺及狐尿刺。《本草衍义补遗》:化热毒,消恶肿结核,解食毒,散滞气。《滇南本草》:敷诸疮肿毒,疥癞癣疮;祛风,消诸疮毒,散瘰疬结核;止小便血,治五淋癃闭,利膀胱。《纲目》:乌须发,壮筋骨。《本草经疏》:蒲公英昧甘平,其性无毒。当是入肝入胃,解热凉血之要药。乳痈属肝经,妇人经行后,肝经主事,故主妇人乳痈肿乳毒,并宜生暖之良。《本草述》:蒲公英,甘而微余苦,是甘平而兼有微寒者也。希雍有曰:甘平之剂点朗肝肾。′昧此一语,则知其入胃而兼入肝肾矣,不然,安能凉血、乌须发,以合于冲任之血脏乎?即是思之,则东垣所谓肾经必用者,尤当推而广之,不当止以前所主治尽之也。《本草新编》:蒲公英,至贱而有大功,借世人不知用之。阳明之火,每至燎原,用白虎汤以泻火,未免太伤胃气。盖胃中之火盛,由于胃中士衰也,泻火而土愈衰矣。故用自虎汤以泻胃火,乃一时之极宜,而不可恃之为经久也。蒲公英亦泻胃火之药,但其气甚平,既能泻火,又不损土,可以长服久服而无碍。凡系阳明之火起者,俱可大剂服之,火退而胃气自生。但其泻火之力甚微,必须多用,一两,少亦五、六钱,始可散邪辅正耳。或问,蒲公英泻火,止泻阳明之火,不识各经之火,亦可尽消之乎?曰,火之最烈者,无过阳明之焰,阳明之火降,而各经余火无不尽消。蒲公英虽非各经之药,而各经之火,见蒲公英而尽伏,即谓蒲公英能消各经之火,亦无不可也。或问,蒲公英与金银花,同是消痈化疡之物,二物毕竟孰胜?夫蒲公英止入阳明、太阴二经,而金银花则无经不入,蒲公英不可与金银花同于功用也。然金银花得蒲公英而其功更大。
是药三分毒,中药保健品一定要控制好剂量,使其毒性降到最低。本发明大大改进中药提取技术,使得中药的有毒成分降到最低,可以使人体吸收,大大提高其利用率。控制剂量;加强“量效关系”和“量毒关系”研究;运用现代技术,体内外方法结合评价。
发明内容
本发明所要解决的技术问题在于,肝胆疾病是严重危害人类健康的常见病多发病,目前无特效药物促进肝细胞再生和防止肝细胞坏死。是药三分毒,中药保健品一定要控制好剂量,使其毒性降到最低。中医认为肝炎多属于湿热蕴结致使胆液外泄侵及皮肤、巩膜等处而发生黄疽,因肝失疏泄,脾失健运而发生食欲不振、恶心呕吐等症状,治疗上宜采取“清热利湿、疏肝利胆”的方法。蒲公英煎剂与注射液有降低四氯化碳引致的大白鼠谷丙转氨酶升高的作用,并能减轻其肝损害,有一定的利胆作用,这可能是蒲公英治疗急性黄疽型肝炎的药理学基础。鉴于蒲公英制剂对实验动物脑垂体,肾上腺等组织无损害作用,临床上未发现任何副作用,而且药源广泛,具有较好的杀菌、保肝、利胆等作用,值得进一步研究其有效成分,改革剂型,扩大临床应用范围。本发明大大改进中药提取技术,使得中药的有毒成分降到最低,可以使人体吸收,大大提高其利用率。
为解决上述技术问题,本发明提供一种排毒除湿利胆的蒲公英口服液,其所述口服液包括以下重量份数的原料药:蒲公英10~50份,茵陈10~20份,溪黄草10~20份,夏枯草10~20份,柴胡10~20份,白芍10~20份,玉米须10~20份,白茅根10~20份,虎杖10~20份,小米草10~20份,半枝莲10~20份,垂盆草10~20份,益母草10~20份,天花粉10~20份,栀子10~20份,墨旱莲10~20份,黄精10~20份,马齿苋10~20份,生地10~20份,板蓝根10~20份,金钱草10~20份。
所述排毒除湿利胆的蒲公英口服液,其所述口服液可以包括以下重量份数的原料药:蒲公英10~30份,茵陈10~15份,溪黄草10~15份,夏枯草10~15份,柴胡10~15份,白芍10~15份,玉米须10~15份,白茅根10~15份,虎杖10~15份,小米草10~15份,半枝莲10~15份,垂盆草10~20份,益母草10~20份,天花粉10~20份,栀子10~20份,墨旱莲10~20份,黄精10~20份,马齿苋10~20份,生地10~20份,板蓝根10~20份,金钱草10~20份。
所述排毒除湿利胆的蒲公英口服液,其所述口服液还可以包括以下重量份数的原料药:蒲公英10~40份,茵陈10~20份,溪黄草10~20份,夏枯草10~20份,柴胡10~20份,白芍10~20份,玉米须10~20份,白茅根10~20份,虎杖10~20份,小米草10~20份,半枝莲10~20份,垂盆草10~15份,益母草10~15份,天花粉10~15份,栀子10~15份,墨旱莲10~15份,黄精10~15份,马齿苋10~15份,生地10~15份,板蓝根10~15份,金钱草10~15份。
为解决上述技术问题,本发明还提供一种排毒除湿利胆的蒲公英口服液的制备方法,其所述口服液的制备步骤包括:
a.蒲公英的制备,萃取,作为组分1;
b.将所述其余原料药放入乙醇中加热回流提取2次,作为组分2;
c.将上述两种提取液组分1和组分2合并,浓缩后加蜂蜜或糊精调和,消毒杀菌后制备成口服液装瓶。
所述步骤a中,可以采摘蒲公英,洗净干燥后切碎,将其浸泡置于有盖不锈钢桶内,加70%乙醇液,质量为粗粉的0.8-1倍,搅拌均匀,湿润密闭放置1小时以上,使充分膨胀;将渗漉筒底部滤板用纱布袋包裹铺平后再将湿润膨胀后的药物样品拌松弄散,然后用不锈钢勺盛粉,均匀的装入渗漉筒,装10-12厘米厚,用T型棒压匀,再按上述操作,一层一层的装入,适当加压,药粉填装不得超过渗漉筒的2/3高处;药粉面上盖不锈钢孔板压牢,打开渗漉筒下面的放料阀,并放一容器,然后缓缓加入70%乙醇液;待排出药粉粉粒之间的空气,并有乙醇流出约20L左右,关闭放料阀,盖上漉筒、浸渍24小时,然后开放料阀进行渗漉,控制渗漉速度一般为1000g药材每分钟流出2~3ml,滤液放入贮液缸内,并将排空时的乙醇液倒入贮液缸;将渗滤液合并静置,加热浓缩至膏状,静置备用,成组分1备用。
所述步骤b中,可以将所述其余原料泡入占其质量10倍量乙醇中,加热提取2次,每次1-2小时,去上清液,合并提取液,100-120目滤过,再经截流分子量为5000-10000的超滤柱超滤,超滤液减压浓缩相对密度为80℃时1.06的浸膏,加热浓缩至膏状,静置备用,成组分2。
所述步骤c中,可以将组分1和组分2合并后,置入双效真空浓缩器中,浓缩至90℃时相对密度为1.36的浓缩液,置0~5℃低温冷藏24小时;将冷藏液加0.3%的助滤剂硅藻土,过滤,滤液再置入双效真空浓缩器中,浓缩至每1ml含0.1g生药量;浓缩后的膏剂加蜂蜜或糊精调和,紫外线消毒杀菌后装瓶。
为解决上述技术问题,本发明也提供一种排毒除湿利胆的蒲公英口服液的制备方法,制备步骤还可以为:
a.将蒲公英加水提取,作为组分1;
b.将蒲公英提取后残渣与所述其余原料药一起加水浸泡、提取2次作为组分2;
c.将组分1、组分2混合浓缩后加蜂蜜调和,紫外线消毒杀菌后装瓶。
所述步骤a中,可以将采摘好的蒲公英洗净,晾晒后放入提取罐加热提取2次,每次1-2小时,去上清液,合并提取液,100-120目滤过,再经截流分子量为5000-10000的超滤柱超滤,超滤液减压浓缩相对密度为80℃时1.06的浸膏,作为组分1;所述步骤b中,将提取的蒲公英渣滓与所述其余原料一起放入占其质量5-10倍量水中,浸泡1-2小时,加热提取2次,每次1-2小时,去上清液,合并提取液,100-120目滤过,将2次提取液合并静置,减压并浓缩至药液浓度为0.6g生药/mL,抽滤后,滤液的相对密度约为20℃时1.08;减压至0.03-0.08MPa,温度保持在60-80℃,浓缩至相对密度为1.20,温度至60℃-70℃的浸膏,作为组分2。
所述步骤c中,可以将组分1与组分2混合后放入减压浓缩罐内,减压回收乙醇,浓缩至药液浓度为0.1g生药/mL,抽滤至滤液的相对密度为20℃时1.06;上述滤液经体积为10L的大孔吸附树脂柱吸附后,用10倍树脂柱体积的去离子水或蒸馏水洗脱,再用5倍树脂柱体积的95%乙醇洗脱,收集乙醇洗脱液,去除溶剂,再调和蜂蜜,紫外线消毒杀菌后装瓶。
肝胆疾病是严重危害人类健康的常见病多发病,目前无特效药物促进肝细胞再生和防止肝细胞坏死。本发明对CCL4引起的急性肝损伤有明显的保护作用,有使SGOT显著降低作用。血清转氨酶升高主要反映肝细胞变性、坏死,细胞膜通透性升高,使肝细胞内GPT、GOT释放入血所致。有文献报道由CCL4中毒引起的动物SGPT、SGOT升高与肝细胞损伤程度呈粗略平行关系。本发明有选择性地降低SGOT作用,大剂量使肝脏指数减少,也说明本药有较好的保肝作用。本发明表明蒲公英清热解毒,利尿散结,用于肝胆疾患,用于低黄疽指数、缩短病程、减轻症状以及恢复肝功能确有显著疗效。
具体实施方式
亚健康状态特别多见于湿热体质。症状表现:湿热质人的型体特征:形体偏胖或消瘦;常有表现:面垢油光、多有痤疮粉刺、常感口干口苦、眼睛红赤、心烦懈怠、身重困倦、小便赤短、大便燥结或黏滞、男性多有阴囊潮湿、女性常有带下增多。病时上述征象加重;舌象:舌质偏红怠黄腻;脉象:多见滑数;心理特征:性情急躁、容易发怒;适应能力:不能耐受湿热环境。常见的皮肤病:痤疮、湿疹、银屑病、汗疱疹,湿癣、脂溢性皮炎、酒糟鼻等。
调养法则:调体方法:分消湿浊,清泄伏火。调体要点:一,宣疏化湿以散热:中医认为“火郁发之”,就是说体内火邪郁滞,要想办法把火发出来,配方中可加入泻火解毒、宣疏清化的成分。二,通利化湿以泄热,根据渗湿于热下之理,使湿热从二便中排泄出来。在疏肝利湿同时佐以通利之白茅根、淡竹叶、薏苡仁、决明子,使热从下泄。
中医认为肝炎多属于湿热蕴结致使胆液外泄侵及皮肤、巩膜等处而发生黄疽,因肝失疏泄,脾失健运而发生食欲不振、恶心呕吐等症状,治疗上宜采取“清热利湿、疏肝利胆”的方法。
我们经过77例急性黄疽型肝炎应用蒲公英制剂治疗的临床观察,初步可看出蒲公英对退黄、降低谷丙转氨酶有一定的作用,并在治疗30天内使89.6%的急性黄疽型肝炎患者临床治愈,在云南等地被认为是治疗病毒性肝炎较好的药物,与大青叶治疗肝胆疗效相似。
蒲公英全草含蒲公英甾醇、胆碱、菊糖、果胶等。根中含蒲公英醇、蒲公英赛醇、ψ-葡公英甾醇、蒲公英甾醇、β-香树脂醇、豆甾醇、β-谷甾醇、胆碱、有机酸、果糖、蔗糖、葡萄糖、葡萄糖甙以及树脂、橡胶等。叶含叶黄素、蝴蝶梅黄素、叶绿醌、维生素C(50~70毫克/100克)和维生素D(5~9毫克/100克)。
花中含山金车二醇、叶黄素和毛莨黄素。花粉中含β-谷甾醇、5z-豆甾-7-烯-3β-醇、叶酸和维生素C。绿色花萼中含叶绿醌。花茎中含β-谷甾醇和β-香树脂醇。又该品含考迈斯托醇、核黄素1.43微克/克和胡萝卜素7.7~8.8毫克%。
(1)抗菌作用:该品注射液试管内对金黄色葡萄球菌耐药菌株、溶血性链球菌有较强的杀菌作用。对肺炎双球菌、脑膜炎球菌、白喉杆菌、绿脓杆菌、痢疾杆菌、伤寒杆菌等及卡他球菌也有一定杀菌作用。本品醇提液1∶400能抑制结核菌,但煎剂1∶100无效。其1∶80的水煎剂能延缓ECHO11病毒细胞病变,醇提物(31mg/kg)能杀死钩端螺旋体,对某些真菌亦有抑制作用。对幽门弯曲杆菌有良好的杀灭作用。
(2)通乳:该品叶有疏通乳脉管之阻塞,促进泌乳的作用。
(3)抗肿瘤作用:药用蒲公英中提取的多糖(Tof-CFr),以40、2、600mg/kgip给于接种MM46肿瘤细胞的C3H小鼠,前期给药未见作用,但11~20天和2~20天的后期隔日给药则有效。对肿瘤细胞的迟延型过敏反应(T-DHR),在ddy-Ehrlich(同种肿瘤)系和C3H-MM46(同系肿瘤)系中,Tof-CFr后期给药其足跖反应与对照组相比均明显上升。在ADMC系中,Tof-CFr与已知能活化巨噬细胞的糖原相比,具有更强的激活能力
(4)利胆作用:国外研究,该品有利胆作用,临床上治疗慢性胆囊痉挛及结石症有效。此外本品尚有利尿健胃,轻泻等作用。
药理试验结果表明,蒲公英煎剂与注射液有降低四氯化碳引致的大白鼠谷丙转氨酶升高的作用,并能减轻其肝损害,有一定的利胆作用,这可能是蒲公英治疗急性黄疽型肝炎的药理学基础。鉴于蒲公英制剂对实验动物脑垂体,肾上腺等组织无损害作用,临床上未发现任何副作用,而且药源广泛,具有较好的杀菌、保肝、利胆等作用,值得进一步研究其有效成分,改革剂型,扩大临床应用范围。
茯苓味甘、淡、性平,入药具有利水渗湿、益脾和胃、宁心安神之功用。现代医学研究:茯苓能增强机体免疫功能,茯苓多糖有明显的抗肿瘤及保肝脏作用。茯苓性味甘淡平,入心、肺、脾经。具有渗湿利水,健脾和胃,宁心安神的功效。可治小便不利,水肿胀满,痰饮咳逆,呕逆,恶阻,泄泻,遗精,淋浊,惊悸,健忘等症。茯苓之利水,是通过健运脾肺功能而达到的,与其它直接利水的中药不同。用于脾虚泄泻,带下茯苓既能健脾,又能渗湿,对于脾虚运化失常所致泄泻、带下,应用茯苓有标本兼顾之效,常与党参、白术、山药等配伍。有可用为补肺脾,治气虚之辅佐药。
茵陈清热利湿;退黄。主治:黄疸、小便不利、湿疮瘙痒、传染性黄疸型肝炎。有利胆,保护肝功能,解热,抗炎,降血脂,降压,扩冠等作用.茵陈有显著的保肝作用,对甲,乙型肝炎,黄疸型肝炎,有显著的疗效。有利胆,促进胆汁分泌,增加胆汁中胆酸和胆红素排出的作用.能增加心脏冠脉血流量,改善微循环,并有降血压,降血脂,抗凝血,利尿解热平喘,驱除蛔虫及抑制多种致病性皮肤真菌与细菌的作用。
夏枯草有清火明目之功效,能治目赤肿痛、头痛等。本品煎剂、水浸出液、乙醇-水浸出液及乙醇浸出液均可明显降低实验动物血压,茎、叶、穗及全草均有降压作用,但穗的作用较明显;本品水煎醇沉液小鼠腹腔注射,有明显的抗炎作用;本品煎剂在体外对痢疾杆菌、伤寒杆菌、霍乱弧菌、大肠杆菌、变形杆菌、葡萄球菌及人型结核杆菌均有一定的抑制作用。夏枯草配伍当归、白芍夏枯草清肝散淤;当归、白芍养血补血.三者伍用有解肝郁、养肝血之功效用于治疗肝郁血虚所致诸症.夏枯草配伍菊花夏枯草清肝火、平肝阳;菊花清热凉肝.二者合用有清肝、凉肝、平肝之功用于治疗肝火上炎、肝经风热引起目赤肿痛;或肝阳上亢导致之头痛、眩晕。
白芍苦,微寒。归肝经。主治功效:清热凉血;活血祛瘀。主温毒发斑;吐血衄血;肠风下血;目赤肿痛;痈肿疮疡;闭经;痛经;崩带淋浊;瘀滞胁痛;疝瘕积聚;跌扑损伤。用于温毒发斑,吐血衄血,目赤肿痛,肝郁胁痛,经闭痛经,症瘕腹痛,跌扑损伤,痈肿疮疡。《本经》:主邪气腹痛,除血痹,破坚积,寒热疝瘕,止痛,利小便,益气。《别录》:通顺血脉,缓中,散恶血,逐贼血,去水气,利膀胱大小肠,消痈肿,时行寒热,中恶腹痛,腰痛。《药性论》:治肺邪气,腹中疞痛,血气积聚,通宣脏腑拥气,治邪痛败血,主时疾骨热,强五脏,补肾气,治心腹坚胀,妇人血闭不通,消瘀血,能蚀脓。
玉米须味甘、淡,性平。有利尿消肿;清肝利胆的功效。主水肿,小便淋沥,黄疸,胆囊炎,胆结石,高血压,糖尿病,乳汁不通。《滇南本草》:宽肠下气。治妇人乳结,乳汁不通,红肿疼痛,怕冷发热,头痛体困。《岭南采药录》:和猪肉煎汤治糖尿病。又治小便淋沥砂石,苦痛不可忍,煎汤频服。
虎杖微苦,微寒。归肝、胆、肺经。功能与主治清热解毒,利胆退黄,祛风利湿,散瘀定痛,止咳化痰。用于关节痹痛,湿热黄疸,经闭,产后瘀血不下,癓瘕,咳嗽痰多,水火烫伤,跌打损伤,痈肿疮毒。虎杖煎剂作用,对外伤出血有明显止血作用,内服对上消化道出血也有止血作用。《日华子本草》:治产后恶血不下,心腹胀满。排脓,主疮疖痈毒,妇人血晕,扑损瘀血,破风毒结气。《滇南本草》:攻诸肿毒,止咽喉疼痛,利小便,走经络。治五淋白浊,痔漏,疮痈,妇人赤白带下。
墨旱莲菊科,一年生草本植物。直立,具匍匐茎;叶对生,披针形;头状花序,腋生或顶生,花白色;瘦果黑色。全国广布种。常见于田梗,沟溪边湿地。全草药用,能收敛、止血、补肝肾之功效。滋补肝肾、凉血止血,可治各种吐血,肠出血等症。捣汁涂眉发,能促进毛发生长,内服有乌发、黑发功效。《唐本草》说,墨旱莲“主血痢,针灸疮发,洪血不可止者敬之”《日华子本草》中也说,墨旱莲可以“排脓,止血,通小肠,敷一切疮并蚕瘑”。
柴胡性味苦、微寒,归肝、胆经。有和解表里,疏肝升阳之功效。用于感冒发热、寒热往来、疟疾、肝郁气滞、胸肋胀痛、脱肛、子宫脱垂、月经不调。和解表里,疏肝解郁,升阳举陷,退热截疟。《本经逢原》:“柴胡,小儿五疳羸热,诸疟寒热,成宜用之。痘疹见点后有寒热,或胁下疼热,于透表药内用之,不使热留少阳经中,则将来无咬牙之患。”
栀子苦寒,能血分而清邪热,宽肠通便,防癌,栀子花含有纤维素,能预防痔疮的发作和直肠癌瘤的发生。栀子花根、叶、果实均可入药,有泻火除烦,消炎祛热、清热利尿,外用解毒之功效。栀子花、果实、叶和根可入药,一般泡茶或煎汤服。栀子含栀子甙、去羟栀子甙、鸡屎藤次甙甲酯及少量山栀甙,有清热利尿、外用解毒、黄疸、血淋痛涩、目红肿痛、火毒疮、降血压等功效。其中栀子果入药,主治热病高烧,心烦不眠,实火牙痛,口舌生疮,鼻规,吐血,眼结膜炎,疮疡肿毒,黄疸型传染性肝炎,蚕豆病,尿血;外用治外伤出血、扭挫伤。根入药主治传染性肝炎,跌打损伤,风火牙痛。《本草纲目》称其“悦颜色,《千金翼》面膏用之。”《滇南本草》称其“泻肺火,止肺热咳嗽,止鼻衄血,消痰。”性味归经:性寒,味甘苦;入肺、肝经。功效主治:清肺止咳,外用止血。主治肺热咳嗽,鼻,咯痰,肿毒等病症。主要成分:栀子花含有三萜成分,栀子花酸A、B和子酸。含挥发油,包括乙酸苄酯、乙酸芳樟酯,另含色素甙、木蜜醇等。另外,还含有碳水化合物、蛋白质、粗纤维及多种维生素。
穿心莲具有消炎解毒作用,临床上曾应用于多种感染性疾病,包括外伤感染、疖、痈、丹毒、上呼吸道感染、急慢性扁桃体炎、急慢性咽喉炎、急慢性支气管炎、急性菌痢、急性胃肠炎、尿路感染、子宫内膜炎、盆腔炎、中耳炎、牙周炎等,均有不同程度的疗效。制剂及用法:现巳制成注射剂、口服胶囊或片剂,用量须视各地生产制剂的不同含量而异。对一般的炎症感染,可以穿心莲干草2~3钱煎服,每日1剂;或片剂(每片相当原生药1g)内服,每次4~8片,每日3~4次。对皮肤化脓性感染创面,可用穿心莲叶研末,制成1∶4水溶液,浸纱布外敷创口。对化脓性中耳炎可制成滴耳剂局部应用,同时内服穿心莲片剂。
溪黄草,拉丁学名Rabdosiaserra(Maxim.)Hara,唇形科喷鼻茶菜属植物线纹香茶菜的全草。溪黄草是民间草药,俗称土黄连等,具有清热利湿、退黄祛湿、凉血散瘀的功效,用于治疗急性黄疸型肝炎、急性胆囊炎、痢疾、肠炎、跌打瘀痛等病症。溪黄草具有清热利湿、退黄祛湿、凉血散瘀的功效,用于治疗急性黄疸型肝炎、急性胆囊炎,痢疾,肠炎,癃闭,跌打瘀痛等病症。其实溪黄草是不能治疗慢性肝炎的,若是急性感染性的黄疸型乙肝可以用溪黄草做急性治疗,便是慢性乙肝还是要到正规的医院做有针对性的治疗,否则有可能延误病情,进而增加治愈的难度。中草药溪黄草对肝炎有一定的效果,但是,治疗小三阳效果却非常有限。
垂盆草(拉丁学名:SedumsarmentosumBunge),别名:狗牙半支、狗牙瓣、鼠牙半支。垂盆草是一味民间流传极广的常用药草,全草入药,有清热解毒、消肿利尿、排脓生肌等的功效。清热利湿;解毒消肿。主湿热黄疸;淋病;泻痢;肺痈;肠痈;疮疖肿毒;蛇虫咬伤;水火烫伤;咽喉肿痛;口腔溃疡及湿疹;带状疱疹。
益母草味辛苦、凉,活血、祛淤、调经、消水,治疗妇女月经不调,胎漏难产,胞衣不下,产后血晕,瘀血腹痛,崩中漏下,尿血、泻血,痈肿疮疡。益母草有利尿消肿、收缩子宫作用的作用,是历代医家用来治疗妇科病的要药。益母草可全草入药,有效成分为益母草素,益母草含益母草碱、水苏碱、益母草定、益母草宁等多种生物碱及苯甲酸、氯化钾等。益母草制剂有兴奋动物子宫的作用,与脑垂体后叶素相似,益母草浸膏及煎剂对子宫有强而持久的兴奋作用,不但能增强其收缩力,同时能提高其紧张度和收缩率。
马齿苋(拉丁学名:PortulacaoleraceaL.)为马齿苋科一年生草本植物。该种为药食两用植物。全草供药用,有清热利湿、解毒消肿、消炎、止渴、利尿作用;种子明目。现代研究,马齿苋还含有丰富的SL3脂肪酸及维生素A样物质。SL3脂肪酸是形成细胞膜,尤其是脑细胞膜与眼细胞膜所必需的物质;维生素A样物质能维持上皮组织如皮肤、角膜及结合膜的正常机能,参与视紫质的合成,增强视网膜感光性能,也参与体内许多氧化过程。
半枝莲(学名:ScutellariabarbataD.Don),分布于阿根廷、巴西南部、乌拉圭以及中国大陆的公园等地,常生于逸生,原产于南美洲。半支莲全草入药,具有清热解毒、活血祛瘀、消肿止痛、抗癌等功能。性寒味酸,全草含多种维生素、微量元素及氨基酸等成分。有凉血解毒,散瘀止痛,消肿和清热利湿之功效。《广西药植图志》:消炎,散瘀止血。治跌打伤及血痢。《南宁市药物志》:消肿止痛。治跌打刀伤及疮疡。《泉州本草》:通络,清热解毒,祛风散血,行气利水,破瘀止痛。内服主血淋,吐血,衄血;外用治毒蛇咬伤,痈疽,疔疮,无名肿毒。
小米草,为玄参科植物小米草、高枝小米草或短腺水米草的全草。学名:EuphrasiapectinataTen,为一年生草本植物,全草具药用价值。味苦;性微寒。归膀胱经,功能主治:清热解毒;利尿。主热病口渴;头痛;肺热咳嗽;咽喉肿痛;热淋;小便不利;口疮;痈肿。
黄精,学名:Polygonatumsibiricum,又名:鸡头黄精、黄鸡菜、笔管菜、爪子参、老虎姜、鸡爪参。为黄精属植物,根茎横走,圆柱状,结节膨大。叶轮生,无柄。药用植物,具有补脾,润肺生津的作用。壮筋骨,益精髓,变白发:黄精、苍术各四斤,枸杞根、柏叶各五斤,天门冬三斤。煮汁一石,同曲十斤,糯米一石,如常酿酒钦。(《纲目》)。补精气:枸杞子(冬采者佳)、黄精等分。为细末,二味招和,捣成块,捏作饼子,干复捣为末,炼蜜为丸,如梧桐子大。每服五十丸,空心温水送下。
板蓝根(常用别名:靛青根、蓝靛根、大青根)是一种中药材。为十字花科植物菘蓝的干燥根,通常在秋季进行采挖,炮制后可入药。其性寒,味先微甜后苦涩,具有清热解毒、预防感冒、利咽之功效。主要用于治疗温毒发斑、舌绛紫暗、烂喉丹痧等疾病。
金钱草为报春花科植物,拉丁文名是LysimachiachristinaeHance。不是马蹄金或者连钱草。金钱草味甘、微苦、性凉。归肝、胆、肾、膀胱经。金钱草是一种常见植物,而且是一种中药材,他主要功效就是可以预防结石和利胆排石可以说对结石有非常好治疗和预防作用,利水通淋;清热解毒;散瘀消肿,清利湿热,沙淋,尿涩作痛,黄疸尿赤,痈肿疔疮,主治肝胆及泌尿系结石;热淋;肾炎水肿;湿热黄疸;疮毒痈肿;毒蛇咬伤;跌打损伤。
天花粉,中药名。《本草正义》:药肆之所谓天花粉者,即以萎根切片用之,有粉之名,无粉之实。天花粉为葫芦科植物栝蒌的根,是一种中药,为清热泻火类药物,其具体功效是清热泻火,生津止渴,排脓消肿。主治:治热病口渴、消渴、黄疸、肺燥咳血、痈肿、痔痿。对于治疗糖尿病,常用它与滋阴药配合使用,以达到标本兼治的作用。
本发明具体实施方式
具体实施例1:
采摘新鲜蒲公英,洗净晾晒后切碎将其泡入5-10倍量的乙醇中,将药粉置有盖不锈钢桶内,加70%乙醇液,质量为粗粉的0.8-1倍,搅拌均匀,湿润密闭放置1小时以上,使充分膨胀;将渗漉筒底部滤板用纱布袋包裹铺平后再将湿润膨胀后的药物样品拌松弄散,然后用不锈钢勺盛粉,均匀的装入渗漉筒,装10-12厘米厚,用T型棒压匀,再按上述操作,一层一层的装入,适当加压,药粉填装不得超过渗漉筒的2/3高处;药粉面上盖不锈钢孔板压牢,打开渗漉筒下面的放料阀,并放一容器,然后缓缓加入70%乙醇液;待排出药粉粉粒之间的空气,并有乙醇流出约20L左右,关闭放料阀,盖上漉筒、浸渍24小时,然后开放料阀进行渗漉,控制渗漉速度一般为1000g药材每分钟流出2~3ml,滤液放入贮液缸内,并将排空时的乙醇液倒入贮液缸;将渗滤液合并静置成组分1。
将其余原料药茵陈,溪黄草,夏枯草,柴胡,白芍,玉米须,白茅根,虎杖,小米草,半枝莲,垂盆草,益母草,天花粉,栀子,墨旱莲,黄精,马齿苋,生地,板蓝根,金钱草,放入10倍量乙醇中,浸泡1-2小时,加热提取2次,每次1-2小时,合并提取液,静置后去上清液,然后放入减压浓缩罐内,减压回收乙醇,浓缩至药液浓度为0.6g生药/mL,抽滤至滤液的相对密度为80℃时1.06的浸膏,成为组分2。
将组分1和组分2合并后置入双效真空浓缩器中,浓缩至90℃时相对密度为1.36的浓缩液,置0~5℃低温冷藏24小时;将冷藏液加0.3%的助滤剂硅藻土,过滤,滤液再置入双效真空浓缩器中,浓缩至每1ml含0.1g生药量;浓缩后的膏剂加糊精调和,紫外线消毒杀菌后装瓶。
具体实施例2:
采摘新鲜蒲公英,洗净晾晒切碎,共5000g,泡入5-10倍量的乙醇中,将药粉置有盖不锈钢桶内,加70%乙醇液,质量为粗粉的0.8-1倍,搅拌均匀,湿润密闭放置1小时以上,使充分膨胀;将渗漉筒底部滤板用纱布袋包裹铺平后再将湿润膨胀后的药物样品拌松弄散,然后用不锈钢勺盛粉,均匀的装入渗漉筒,装10-12厘米厚,用T型棒压匀,再按上述操作,一层一层的装入,适当加压,药粉填装不得超过渗漉筒的2/3高处;药粉面上盖不锈钢孔板压牢,打开渗漉筒下面的放料阀,并放一容器,然后缓缓加入70%乙醇液;待排出药粉粉粒之间的空气,并有乙醇流出约20L左右,关闭放料阀,盖上漉筒、浸渍24小时,然后开放料阀进行渗漉,控制渗漉速度一般为1000g药材每分钟流出2~3ml,滤液放入贮液缸内,并将排空时的乙醇液倒入贮液缸;将渗滤液合并静置成组分1。
将茵陈1500g,溪黄草1500g,夏枯草1500g,柴胡1500g,白芍1500g,玉米须1500g,白茅根1500g,虎杖1500g,小米草1500g,半枝莲1500g,垂盆草1500g,益母草1500g,天花粉1500g,栀子1500g,墨旱莲1500g,黄精1500g,马齿苋1500g,生地1500g,板蓝根1500g,金钱草1500g,将其余原料药的药放入10倍量乙醇中,浸泡1-2小时,加热提取2次,每次1-2小时,合并提取液,静置后去上清液,然后放入减压浓缩罐内,减压回收乙醇,浓缩至药液浓度为0.6g生药/mL,抽滤至滤液的相对密度为20℃时1.06的浸膏,成为组分2。
将组分1和组分2合并后置入双效真空浓缩器中,浓缩至90℃时相对密度为1.35的浓缩液,置0~5℃低温冷藏24小时;将冷藏液加0.3%的助滤剂硅藻土,过滤,滤液再置入双效真空浓缩器中,浓缩至每1ml含0.1g生药量;浓缩后的膏剂加糊精调和,紫外线消毒杀菌后装瓶。
具体实施例3:采摘新鲜蒲公英,洗净晾晒,共4500g后,放入提取罐加热提取2次,每次1-2小时,去上清液,合并提取液,100-120目滤过,再经截流分子量为5000-10000的超滤柱超滤,超滤液减压浓缩相对密度为80℃时1.06的浸膏,作为组分1,将所述其余原料将茵陈1100g,溪黄草1200g,夏枯草1100g,柴胡1100g,白芍1100g,玉米须1100g,白茅根1100g,虎杖1100g,小米草1100g,半枝莲1200g,垂盆草1100g,益母草1100g,天花粉1100g,栀子1100g,墨旱莲1100g,黄精1100g,马齿苋1100g,生地1100g,板蓝根1100g,金钱草1100g,放入5-10倍量水中,浸泡1-2小时,加热提取2次,每次1-2小时,去上清液,合并提取液,100-120目滤过,将2次提取液合并静置,减压回收乙醇,并浓缩至药液浓度为0.6g生药/mL,抽滤后,滤液的相对密度约为20℃时1.08;减压至0.03-0.08MPa,温度保持在60-80℃,浓缩至相对密度为1.20,温度至60℃-70℃的浸膏,作为组分2。将组分1组分2混合置入双效真空浓缩器中,浓缩至90℃时相对密度为1.05的浓缩液,置0~5℃低温冷藏24小时;将冷藏液加0.3%的助滤剂硅藻土,过滤,滤液再置入双效真空浓缩器中,浓缩至每1ml含0.1g生药量;浓缩后的膏剂加组分1的精油然后加蜂胶调和,紫外线消毒杀菌后装瓶。
具体实施例4:采摘新鲜蒲公英,洗净晾晒,共4500g后,泡入10倍量乙醇中,加热提取2次,每次1-2小时,去上清液,合并提取液,100-120目滤过,再经截流分子量为5000-10000的超滤柱超滤,超滤液减压浓缩相对密度为80℃时1.06的浸膏,加热浓缩至膏状,静置备用,成组分1。将茵陈1100g,溪黄草1200g,夏枯草1100g,柴胡1100g,白芍1100g,玉米须1100g,白茅根1100g,虎杖1100g,小米草1100g,半枝莲1200g,垂盆草1100g,益母草1100g,天花粉1100g,栀子1100g,墨旱莲1100g,黄精1100g,马齿苋1100g,生地1100g,板蓝根1100g,金钱草1100g,将所述原料药放入粉碎机粉碎后,将颗粒物放入乙醇中加热回流提取2次,每次1~2小时,将2次提取液合并静置;将上述乙醇提取过的药渣加10倍量水加热回流提取2次,每次1~2小时,将2次提取液合并静置,将上述两种提取液合并,作为组分2;合并组分1组分2减压浓缩相对密度为80℃时1.36的滤液,回收乙醇,调入蜂胶,紫外线杀菌后装瓶。
试验例1:本发明急性毒性试验
一、试验材料:
动物:昆明种小鼠,体重21-24g,雌雄各半,山东大学生物试验室育种。药物:本发明口服液(按实施方法2制备)。
二、方法:
1、LD50计算:采用改良寇氏法,将小鼠随机分成5组,每组10只,雌雄各半,将栓剂溶解,配成最大浓度,按小鼠最大允许容量给药,所给剂量按生药量依次为18,14.4,11.5,9.2,7.4(g.kg-1),在动物禁食(不禁水)18小时后,一日内分两次给药(间隔半小时),每次0.5ml,观察动物死亡情况。
2、最大耐受剂量测定(MTD值):取小鼠20只,雌雄各10只。将栓剂加蒸馏水溶解,配成最高浓度,按动物的最大耐受量,以注射灌喂器能抽动为准。在动物禁食(不禁水)18小时后,一日内分两次给药(间隔半小时),每次0.5ml(每ml含生药0.36g),总药量为18g生药/kg.d,相当临床成人50Kg体重用量的300倍。给药后连续观察7天。
三、试验结果:
在LD50计算中当用最大允许浓度和最大允许容量给予小鼠时(18g/Kg.d),未见小鼠死亡,即未测出LD50,只可求最大耐受剂量,在7天观察期中,动物其食欲、活动、毛色、精神状态等皆正常,发育正常,未见有死亡。即选用相当于临床剂量的300倍药量,并无不良反应发生,表明急性毒性极小,MTD>18g/Kg.d。
试验例2:本发明急性皮肤刺激试验报告
1、实验目的:检测本发明对实验动物皮肤的刺激/腐蚀作用和强度
2、材料和方法:
2.1.受试物:本发明口服液(按实施例方法2制得)
2.2.实验动物:壹级大耳白种家兔,10只,雌性,体重2.1-2.3kg;由青岛大学医学院生物系实验动物中心提供;
2.3.试验方法:
选用皮肤完好的健康家兔10只,于试验前24小时将其背部脊柱两侧被毛剪掉,去毛面积左、右各约4cm×4cm。试验时取受试物0.2ml涂于2.5cm×2.5cm的二层纱布上,敷贴于一侧去毛皮肤表面,油纸覆盖,胶布固定。另一侧皮肤作为空白对照。封闭4小时后,去除覆盖物,并用温水清洗去残留受试物,于去除受试物后的1、24和48小时观察涂抹部位皮肤反应,并评分。
3、实验结果:实验动物皮肤未出现任何红斑,红肿,发炎现象。
4、小结:根据《消毒技术规范》(1999)中皮肤刺激反应评分标准判定,本发明对动物皮肤刺激强度属无刺激性。
实施例3:长期毒性实验资料
1、实验方法
将豚鼠随机份成4组,每组15只。在豚鼠背部脊柱两侧将脱毛剂均匀涂上,使其脱毛范围约40平方厘米。洗净脱毛剂,观察24小时后每组豚鼠分别涂本发明口服液溶液0.2、0.4和0.8ml,分别含生药92、184和368mg,另一组涂溶媒0.8ml每日二次,连续30天,观察豚鼠的一般情况,实验结束后处死动物进行血液学、血液生化及病理学检查。
2、结果
上述三组用药豚鼠躯干去毛区,未见局部皮肤有水肿、充血、红斑、出血点及溃疡。用药组与对照组动物毛发色泽、摄食、四肢活动等对照组无明显差异,血液生化检查,用药组与对照组均在正常范围。病理组织学检查,实验各组心、肝、肾及局部皮肤均未见明显病变。提示,本发明中药口服液长期用药对局部皮肤及全身重要脏器均未见明显的毒性作用。
试验结果表明:本发明口服液实验安全。该药对乙型链球菌、金黄色葡萄球菌、大肠杆菌的最小抑制浓度为1∶150,淋球菌为1∶150,白色念珠菌为1∶300,对1∶20稀释度时的杀灭时间为5分钟,1∶50时为10分钟,1∶100时为20分钟,1∶200时为40分钟,1∶400时为8小时。
药理学实验:
蒲公英对正常小鼠由四氯化碳引起的肝损伤有明显保护作用,表现为SGOT显著降低,使肝体比降低(大剂量)。对正常大鼠有显著的利胆作用,胆汁流量增加持续2h。熊去氧胆酸流量增加持续1小时。胆汁中胆固醇、胆红素给药前和给药后组间比较未见显著差异性。为此我们进行了实验研究。
1、材料与方法
药物:本发明蒲公英提醇沉液的制备:取一定量本发明原料药,水煎两次,水浴上浓缩至一定体积后加95乙醇沉淀杂质,过液,滤液回收乙醇。配成100%浓度。
对照组为白云山消炎利胆片,国药准字Z44022243。熊去氧胆酸为日本三菱化成生产。
动物ICR小鼠,SD大鼠均由本院动物研究室提供。
1.1对四氯化碳引起的小鼠肝损伤的保护作用:雄性小鼠78只,体重18-23g,按体重随机分层分成六组,每组13只。本发明3个剂量组2.5g/kg、5.0g/kg、10.0g/kg,阳性对照药白云山消炎利胆片10g/kg,模型组,水对照组每天灌胃给药一次,连续6d,于第六天给药后1h除水对照组外其余各组均皮下注射0.15的四氯化碳菜油5ml/kg。16h后摘眼球取血用北京化工厂产的试剂盒测定血清SGPT、SGOT。解剖出肝脏称重,根据处死时体重计算每只小鼠的肝体比、数据以均值士标准差表示,组间进行t检验。
1.2对正常大鼠胆汁流量的影响1.2.1
胆汁流量的测定:取大鼠60只,雄性,体重250~350g,称重随机分成五组,每组12只,实验前禁食12h,不禁水。实验以10%乌拉坦1.0g/kg腹腔注射麻醉,仰位固定于手术台,沿腹正中线切开腹壁,找出十二指肠,在降部肠系膜中找到白色有韧性的胆管,在其下穿二根丝线,结扎乳头部,向肝脏方向作“V”形切口,插入硬质塑料管,结扎固定,即可见有淡黄绿色胆汗流出,试管收集胆汁,术后以盐水纱布覆盖腹腔,待稳定1h后,先收集30min的胆汁,作为给药前的基础值,然后分组给药(经十二指肠)。本发明3个剂量组2.5g/kg、5.0g/kg、10.0g/kg,水对照组,阳性药熊去氧胆酸0.5g/kg。给药后每隔30min收集测量1次胆汁。共4h。
1.2.2胆汁成分的测定:将给药前,给药后4h收集的胆汁测定胆红素(伊利康生物技术有限公司生产,咖啡因法)。胆固醇含量测定用东欧生物工程公司生产的试剂盒,酶法测定。
2实验结果
2.1对四氯化碳引起的小鼠肝损伤的保护作用:四氯化碳引起的SGPT、SGOT显著升高P<0.01,说明造型成功。本发明使SGOT显著降低三个剂量组均P<O.05,本发明对SGPT无明显影响。白云山消炎利胆片使SGPT、SGOT显著降低(P-~O.05)。10g/kg组使肝体比显著低于四氯化碳模型组。详见表1。
表1本发明对四氯化碳中毒小鼠血清转氨酶的影响(X±S)
注:组间进行t检验,与四氯化碳组比*P<0.05,**P<0.01
2.2对正常大鼠胆汁流量的影响:本发明2.5g/kg组使正常大鼠胆汁流量增加,持续2h,以给药后的30min增加最显著<0.05)。5.0g/kg组给药2h各时相都显著增加<0.05.10.0g/kg组给药后90min内各时相都比对照组显著升高(P<0.01,P<0.05)。阳性药熊去氧胆酸也使流量增加,持续1h。P<0.05详见表2。
表2本发明对麻醉大鼠胆汁流量的影响(X±S)
注t以给药前流量为100%,组问进行t检验,与对照组比*P<0.05,**P<0.01.本发明给药前、给药后涓定胆汁中胆红素和胆同醇含量与对照组相比未见显著差异。详见表3。
表3本发明对大鼠胆汁中胆固醇、胆红素排出量的影响(X±S)
讨论:
中医认为肝炎多属于湿热蕴结致使胆液外泄侵及皮肤、巩膜等处而发生黄疽,因肝失疏泄,脾失健运而发生食欲不振、恶心呕吐等症状,治疗上宜采取“清热利湿、疏肝利胆”的方法。
我们经过77例急性黄疽型肝炎应用蒲公英制剂治疗的临床观察,初步可看出蒲公英对退黄、降低谷丙转氨酶有一定的作用,并在治疗30天内使89.6%的急性黄疽型肝炎患者临床治愈,在云南等地被认为是治疗病毒性肝炎较好的药物,与大青叶治疗肝胆疗效相似。
药理试验结果表明,蒲公英煎剂与注射液有降低四氯化碳引致的大白鼠谷丙转氨酶升高的作用,并能减轻其肝损害,有一定的利胆作用,这可能是蒲公英治疗急性黄疽型肝炎的药理学基础。鉴于蒲公英制剂对实验动物脑垂体,肾上腺等组织无损害作用,临床上未发现任何副作用,而且药源广泛,具有较好的杀菌、保肝、利胆等作用,值得进一步研究其有效成分,改革剂型,扩大临床应用范围。
临床试验
自2013年5月至2015年6月,采用自拟清肝利湿降脂汤治疗脂肪肝80例,取得显著疗效,临床资料本组80例中为体检发现者和同行单位的门诊患者,年龄35-50岁,平均44岁;疗程1-6年不等。两组资料经Ridit检验,年龄、病程等方面均无显著差异性。具有可比性。诊断依据临床表现和影像学及实验室检查,均符合脂肪肝特征。按就诊顺序随机分为治疗组和对照组各40例。诊断标准:国家中医药管理局中医肝病重点专科写作组主编《中医肝病诊疗常规》2005年10月第1版。
治疗方法
治疗组:本发明口服液,方药组成蒲公英30g,茵陈12g,溪黄草12g,夏枯草11g,柴胡11g,白芍12g,玉米须12g,白茅根11g,虎杖12g,小米草12g,半枝莲13g,垂盆草13g,益母草12g,天花粉12g,栀子11g,墨旱莲12g,黄精12g,马齿苋12g,生地12g,板蓝根12g,金钱草11g,按实施例方法2制备,每日3瓶,连服2个月后,停服1周,再服1个月为1疗程。
对照组:强肝胶囊(石家庄东方药业有限公司生产)国药准字:ZL0980012,1次5粒,ld3次。两个月1疗程。治疗期间停服任何药物。
疗效标准:临床治愈:症状、体征完全消失,肝功能正常,血脂基本正常,B超提示肝脏声像恢复正常。有效:症状体征消失,谷丙转氨酶及血脂升高部分下降50%以上,B超提示脂肪肝声像图减轻。无效:未达以上标准者。
治疗结果见表1。
表1治疗组与对照组的疗效比较
| 组别 | 例数 | 痊愈 | 有效 | 无效 | 总有效率* |
| 治疗组 | 40 | 16 | 15 | 9 | 77.5% |
| 对照组 | 40 | 8 | 13 | 19 | 52.5% |
*临床治愈与有效视为有效例数,经统计学处理两组比较有明显差异(P<0.05),治疗组明显优于对照组。
讨论:脂肪肝是近年来才引起医学界高度重视的肝脏脂肪代谢紊乱性疾病。现代医学认为本病主要由脂类摄人过多、肥胖、或毒物(乙醇),或遗传与代谢因素引起过量的脂肪在肝内堆积致病。查阅古典,祖国医学虽没有脂肪肝之病名,但在历代医籍中、有一些类似本病的记载。《灵枢.卫气失常》即已指出人体内有“脂、”有“膏”有“肉”、并根据人体形体的不同而分为“脂人”、“膏人、”“肉人”。其云:“膏者,多气而皮纵缓,故能纵腹垂腴。肉者,身体容大。脂者,其身收小。”张志聪《灵枢集注》云:“中焦之气,蒸津液化.其津微溢于外则皮肉膏肥。余于肉,则膏脂丰满。”张景岳《类经》亦云:“精液和合而为膏,以填补骨空之中,则为脑为髓,为精为血。”由此可见,上文描述之膏脂与现代医学之脂类物质相类似。同时也说明膏脂实乃人体的生理组成成分之一,属精液之范畴,并可与津液其他成分相互转化,津从浊化为膏,凝则为脂。正常脂膏随血液的运行营养五脏六腑,四肢白骸以及脑髓。若禀赋不足,饮食不节,脾胃失调,情志内伤,肝胆失调,年老体弱,身虚不足等原因,而致摄食过多或传输、利用、排泄异常,皆可是血中脂膏堆积,过多的脂膏浊化。而成为湿浊、痰饮、侵淫隧道,使气血运行障碍,血瘀的本质具体表现在微循环障碍,血流的动力学异常和血液流变学异常。而痰浊与血瘀同是机体脏腑功能失调的病理产物,最终形成肝经痰凝瘀滞,肝内脂肪瘀积的病理变化,而出现“痰证”、“瘀证”、“脉痹”等证。
综合看来当属肝痞、胁痛、症瘕、积聚等范畴基于上述认识,遵循疏肝而降脂、利湿兼化痰、活血而化瘀之大法,采用疏肝降脂、化痰祛湿、活血散结、软坚消积之中药。方中夏枯草、黄芩以疏肝降脂之功;薏仁具有较强的活血化瘀、利水渗湿的作用;白术补脾益气;佛手宽中理气、和胃化痰、消积除痞;夏枯草、黄芩清利解毒,使之清解通利而护肝。诸药配伍,疏利通降而不伤正,益气补中而不壅结,以达到扶正祛邪,清热利湿,排毒减肥之目的。
Claims (10)
1.一种排毒除湿利胆的蒲公英口服液,其特征在于,所述口服液包括以下重量份数的原料药:蒲公英10~50份,茵陈10~20份,溪黄草10~20份,夏枯草10~20份,柴胡10~20份,白芍10~20份,玉米须10~20份,白茅根10~20份,虎杖10~20份,小米草10~20份,半枝莲10~20份,垂盆草10~20份,益母草10~20份,天花粉10~20份,栀子10~20份,墨旱莲10~20份,黄精10~20份,马齿苋10~20份,生地10~20份,板蓝根10~20份,金钱草10~20份。
2.根据权利要求1所述排毒除湿利胆的蒲公英口服液,其特征在于,所述口服液包括以下重量份数的原料药:蒲公英10~30份,茵陈10~15份,溪黄草10~15份,夏枯草10~15份,柴胡10~15份,白芍10~15份,玉米须10~15份,白茅根10~15份,虎杖10~15份,小米草10~15份,半枝莲10~15份,垂盆草10~20份,益母草10~20份,天花粉10~20份,栀子10~20份,墨旱莲10~20份,黄精10~20份,马齿苋10~20份,生地10~20份,板蓝根10~20份,金钱草10~20份。
3.根据权利要求1所述排毒除湿利胆的蒲公英口服液,其特征在于,所述口服液包括以下重量份数的原料药:蒲公英10~40份,茵陈10~20份,溪黄草10~20份,夏枯草10~20份,柴胡10~20份,白芍10~20份,玉米须10~20份,白茅根10~20份,虎杖10~20份,小米草10~20份,半枝莲10~20份,垂盆草10~15份,益母草10~15份,天花粉10~15份,栀子10~15份,墨旱莲10~15份,黄精10~15份,马齿苋10~15份,生地10~15份,板蓝根10~15份,金钱草10~15份。
4.一种如权利要求1~3中任一项所述排毒除湿利胆的蒲公英口服液的制备方法,其特征在于,所述口服液的制备步骤包括:
a.蒲公英的制备,萃取,作为组分1;
b.将所述其余原料药放入乙醇中加热回流提取2次,作为组分2;
c.将上述两种提取液组分1和组分2合并,浓缩后加蜂蜜或糊精调和,消毒杀菌后制备成口服液装瓶。
5.根据权利要求4所述排毒除湿利胆的蒲公英口服液的制备方法,其特征在于,所述步骤a中,采摘蒲公英,洗净干燥后切碎,将其浸泡置于有盖不锈钢桶内,加70%乙醇液,质量为粗粉的0.8-1倍,搅拌均匀,湿润密闭放置1小时以上,使充分膨胀;将渗漉筒底部滤板用纱布袋包裹铺平后再将湿润膨胀后的药物样品拌松弄散,然后用不锈钢勺盛粉,均匀的装入渗漉筒,装10-12厘米厚,用T型棒压匀,再按上述操作,一层一层的装入,适当加压,药粉填装不得超过渗漉筒的2/3高处;药粉面上盖不锈钢孔板压牢,打开渗漉筒下面的放料阀,并放一容器,然后缓缓加入70%乙醇液;待排出药粉粉粒之间的空气,并有乙醇流出约20L左右,关闭放料阀,盖上漉筒、浸渍24小时,然后开放料阀进行渗漉,控制渗漉速度一般为1000g药材每分钟流出2~3ml,滤液放入贮液缸内,并将排空时的乙醇液倒入贮液缸;将渗滤液合并静置,加热浓缩至膏状,静置备用,成组分1备用。
6.根据权利要求4所述排毒除湿利胆的蒲公英口服液的制备方法,其特征在于,所述步骤b中,将所述其余原料泡入占其质量10倍量乙醇中,加热提取2次,每次1-2小时,去上清液,合并提取液,100-120目滤过,再经截流分子量为5000-10000的超滤柱超滤,超滤液减压浓缩相对密度为80℃时1.06的浸膏,加热浓缩至膏状,静置备用,成组分2。
7.根据权利要求4所述排毒除湿利胆的蒲公英口服液的制备方法,其特征在于,所述步骤c中,将组分1和组分2合并后,置入双效真空浓缩器中,浓缩至90℃时相对密度为1.36的浓缩液,置0~5℃低温冷藏24小时;将冷藏液加0.3%的助滤剂硅藻土,过滤,滤液再置入双效真空浓缩器中,浓缩至每1ml含0.1g生药量;浓缩后的膏剂加蜂蜜或糊精调和,紫外线消毒杀菌后装瓶。
8.一种如权利要求1~3中任一项所述排毒除湿利胆的蒲公英口服液的制备方法,其特征在于,制备步骤还可以为:
a.将蒲公英加水提取,作为组分1;
b.将蒲公英提取后残渣与所述其余原料药一起加水浸泡、提取2次作为组分2;
c.将组分1、组分2混合浓缩后加蜂蜜调和,紫外线消毒杀菌后装瓶。
9.根据权利要求8所述排毒除湿利胆的蒲公英口服液的制备方法,其特征在于,所述步骤a中,将采摘好的蒲公英洗净,晾晒后放入提取罐加热提取2次,每次1-2小时,去上清液,合并提取液,100-120目滤过,再经截流分子量为5000-10000的超滤柱超滤,超滤液减压浓缩相对密度为80℃时1.06的浸膏,作为组分1;所述步骤b中,将提取的蒲公英渣滓与所述其余原料一起放入占其质量5-10倍量水中,浸泡1-2小时,加热提取2次,每次1-2小时,去上清液,合并提取液,100-120目滤过,将2次提取液合并静置,减压并浓缩至药液浓度为0.6g生药/mL,抽滤后,滤液的相对密度约为20℃时1.08;减压至0.03-0.08MPa,温度保持在60-80℃,浓缩至相对密度为1.20,温度至60℃-70℃的浸膏,作为组分2。
10.根据权利要求8所述排毒除湿利胆的蒲公英口服液的制备方法,其特征在于,所述步骤c中,将组分1与组分2混合后放入减压浓缩罐内,减压回收乙醇,浓缩至药液浓度为0.1g生药/mL,抽滤至滤液的相对密度为20℃时1.06;上述滤液经体积为10L的大孔吸附树脂柱吸附后,用10倍树脂柱体积的去离子水或蒸馏水洗脱,再用5倍树脂柱体积的95%乙醇洗脱,收集乙醇洗脱液,去除溶剂,再调和蜂蜜,紫外线消毒杀菌后装瓶。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510889661.9A CN105343625A (zh) | 2015-12-04 | 2015-12-04 | 一种排毒除湿利胆的蒲公英口服液及其制备方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510889661.9A CN105343625A (zh) | 2015-12-04 | 2015-12-04 | 一种排毒除湿利胆的蒲公英口服液及其制备方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105343625A true CN105343625A (zh) | 2016-02-24 |
Family
ID=55319784
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510889661.9A Pending CN105343625A (zh) | 2015-12-04 | 2015-12-04 | 一种排毒除湿利胆的蒲公英口服液及其制备方法 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105343625A (zh) |
Cited By (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105727032A (zh) * | 2016-03-30 | 2016-07-06 | 黄山树德堂食品饮料有限公司 | 一种平肝明目的保健饮料及其制备方法 |
| CN105748901A (zh) * | 2016-03-30 | 2016-07-13 | 黄山树德堂食品饮料有限公司 | 一种保健饮料配方及其制备方法 |
| CN105853773A (zh) * | 2016-03-30 | 2016-08-17 | 黄山树德堂食品饮料有限公司 | 一种清热去火、平肝明目的菊花保健茶及其制备方法 |
| CN105920189A (zh) * | 2016-07-10 | 2016-09-07 | 马佳 | 一种治疗肝肾亏虚型足跟痛的中药组合物及其制备方法 |
| CN105998228A (zh) * | 2016-07-10 | 2016-10-12 | 马佳 | 治疗足跟痛的中药制备方法及其熏洗浸泡剂 |
| CN105998448A (zh) * | 2016-08-02 | 2016-10-12 | 马佳 | 提高免疫力的桑葚口服液制备方法及其口服液 |
| CN106074813A (zh) * | 2016-07-10 | 2016-11-09 | 马佳 | 一种治疗足跟痛的中药熏洗浸泡剂及其制备方法 |
| CN106110204A (zh) * | 2016-08-02 | 2016-11-16 | 马佳 | 一种提高免疫力的蒲公英口服液及其制备方法 |
| CN106177134A (zh) * | 2016-08-02 | 2016-12-07 | 马佳 | 一种排毒养颜的菊花口服液及其制备方法 |
| CN106177540A (zh) * | 2016-08-02 | 2016-12-07 | 马佳 | 一种清热止痛的蒲公英口服液及其制备方法 |
| CN106237130A (zh) * | 2016-08-02 | 2016-12-21 | 马佳 | 清热止痛的蒲公英口服液制备方法及其口服液 |
| CN106237234A (zh) * | 2016-08-02 | 2016-12-21 | 马佳 | 提高免疫力的蒲公英口服液制备方法及其口服液 |
| CN106236960A (zh) * | 2016-08-02 | 2016-12-21 | 马佳 | 一种提高免疫力的桑葚保健口服液及其制备方法 |
| CN106563075A (zh) * | 2016-07-10 | 2017-04-19 | 马佳 | 一种延缓衰老的仙茅保健口服液及其制备方法 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103990081A (zh) * | 2014-06-17 | 2014-08-20 | 刘青振 | 一种中药组合物及其在制备治疗婴幼儿黄疸药物中的用途 |
| CN104208581A (zh) * | 2014-08-27 | 2014-12-17 | 青岛恒波仪器有限公司 | 一种预防酒精肝的五味子保健口服液及其制备方法 |
-
2015
- 2015-12-04 CN CN201510889661.9A patent/CN105343625A/zh active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103990081A (zh) * | 2014-06-17 | 2014-08-20 | 刘青振 | 一种中药组合物及其在制备治疗婴幼儿黄疸药物中的用途 |
| CN104208581A (zh) * | 2014-08-27 | 2014-12-17 | 青岛恒波仪器有限公司 | 一种预防酒精肝的五味子保健口服液及其制备方法 |
Non-Patent Citations (1)
| Title |
|---|
| 王西周: "茵陈赤虎汤治疗小儿黄疸性肝炎64例小结", 《陕西中医》 * |
Cited By (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105727032A (zh) * | 2016-03-30 | 2016-07-06 | 黄山树德堂食品饮料有限公司 | 一种平肝明目的保健饮料及其制备方法 |
| CN105748901A (zh) * | 2016-03-30 | 2016-07-13 | 黄山树德堂食品饮料有限公司 | 一种保健饮料配方及其制备方法 |
| CN105853773A (zh) * | 2016-03-30 | 2016-08-17 | 黄山树德堂食品饮料有限公司 | 一种清热去火、平肝明目的菊花保健茶及其制备方法 |
| CN106074813A (zh) * | 2016-07-10 | 2016-11-09 | 马佳 | 一种治疗足跟痛的中药熏洗浸泡剂及其制备方法 |
| CN105998228A (zh) * | 2016-07-10 | 2016-10-12 | 马佳 | 治疗足跟痛的中药制备方法及其熏洗浸泡剂 |
| CN105920189A (zh) * | 2016-07-10 | 2016-09-07 | 马佳 | 一种治疗肝肾亏虚型足跟痛的中药组合物及其制备方法 |
| CN106563075A (zh) * | 2016-07-10 | 2017-04-19 | 马佳 | 一种延缓衰老的仙茅保健口服液及其制备方法 |
| CN105998448A (zh) * | 2016-08-02 | 2016-10-12 | 马佳 | 提高免疫力的桑葚口服液制备方法及其口服液 |
| CN106110204A (zh) * | 2016-08-02 | 2016-11-16 | 马佳 | 一种提高免疫力的蒲公英口服液及其制备方法 |
| CN106177134A (zh) * | 2016-08-02 | 2016-12-07 | 马佳 | 一种排毒养颜的菊花口服液及其制备方法 |
| CN106177540A (zh) * | 2016-08-02 | 2016-12-07 | 马佳 | 一种清热止痛的蒲公英口服液及其制备方法 |
| CN106237130A (zh) * | 2016-08-02 | 2016-12-21 | 马佳 | 清热止痛的蒲公英口服液制备方法及其口服液 |
| CN106237234A (zh) * | 2016-08-02 | 2016-12-21 | 马佳 | 提高免疫力的蒲公英口服液制备方法及其口服液 |
| CN106236960A (zh) * | 2016-08-02 | 2016-12-21 | 马佳 | 一种提高免疫力的桑葚保健口服液及其制备方法 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105343625A (zh) | 一种排毒除湿利胆的蒲公英口服液及其制备方法 | |
| CN102145064B (zh) | 一种治疗老年性阴道炎的中药组合物及其制备方法 | |
| CN103417904B (zh) | 一种治疗慢性唇炎的中药组合物及其制备方法 | |
| CN102205107B (zh) | 一种治疗十二指肠溃疡的中药制剂及其制备方法 | |
| CN101972338A (zh) | 一种治疗小儿上呼吸道感染的中药制剂及其制备方法 | |
| CN102784363A (zh) | 一种治疗胰腺癌的中药组合物及其制备方法 | |
| CN102058715B (zh) | 一种治疗慢性前列腺炎的中药制剂及其制备方法 | |
| CN102178814A (zh) | 一种治疗滴虫性阴道炎的中药组合物及其制备方法 | |
| CN104958607A (zh) | 一种治疗妇女更年期灼口综合征的中药组合物及方法 | |
| CN102988675B (zh) | 一种治疗慢性前列腺炎的中药组合物及其制备方法 | |
| CN103041262B (zh) | 一种治疗慢性前列腺炎的中药灌肠剂及其制备方法 | |
| CN104587302A (zh) | 一种治疗急性阑尾炎的中药制剂 | |
| CN105412697A (zh) | 一种清热除湿、保肝利胆的佩兰口服液及其制备方法 | |
| CN105233052A (zh) | 一种治疗轻度脂肪肝的中药制剂及其制备方法 | |
| CN104644967A (zh) | 一种治疗i型糖尿病的药物组合物及其应用 | |
| CN104547798A (zh) | 一种治疗慢性肠炎、阑尾炎的中药制剂及其制备方法 | |
| CN103041263B (zh) | 一种治疗慢性前列腺炎的中药直肠给药栓剂及其制备方法 | |
| CN105169278A (zh) | 一种保肝利胆的蒲公英口服液及其制备方法 | |
| CN105233056A (zh) | 一种清热除湿、利胆排毒的大黄口服液及其制备方法 | |
| CN105233078A (zh) | 一种用于治疗病毒性肝炎的中药组合物 | |
| CN105343516A (zh) | 一种治疗肝火上炎的夏枯草口服液及其制备方法 | |
| CN105106696A (zh) | 一种治疗慢性前列腺炎的中药组合物 | |
| CN105288315A (zh) | 一种清热除湿、利胆排毒的金钱草口服液及其制备方法 | |
| CN105213888A (zh) | 一种除湿排毒减肥的夏枯草口服液及其制备方法 | |
| CN105288316A (zh) | 一种清热除湿、保肝利胆的牛筋草口服液及其制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20160224 |